Capecitabine
Information
- Drug Name
- Capecitabine
- Description
- Entry(CIViC)
- 10
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| Her2-receptor positive breast cancer |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 17192538 | Detail |
| Her2-receptor positive breast cancer |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 19289619 | Detail |
| cancer |
DPYD c.1905+1G>A ( ENST00000370192.8 ) DPYD c.1905+1G>A ( ENST00000370192.8 ) |
A |
Predictive
|
Supports
|
Adverse Response | Common Germline | 5 | 23988873 | Detail |
| cancer |
DPYD p.Ile560Ser (p.I560S) ( ENST00000370192.8 ) DPYD p.Ile560Ser (p.I560S) ( ENST00000370192.8 ) |
A |
Predictive
|
Supports
|
Adverse Response | Common Germline | 5 | 23988873 | Detail |
| cancer | DPYD RS67376798 HOMOZYGOSITY DPYD RS67376798 HOMOZYGOSITY | A |
Predictive
|
Supports
|
Adverse Response | Common Germline | 5 | 23988873 | Detail |
| pancreatic cancer | ERBB2 OVEREXPRESSION ERBB2 OVEREXPRESSION | B |
Predictive
|
Does Not Support
|
Sensitivity/Response | Somatic | 4 | 22374460 | Detail |
| salivary gland cancer | ERBB2 OVEREXPRESSION ERBB2 OVEREXPRESSION | C |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
3 | 20504363 | Detail |
| colorectal cancer | TP53 WILD TYPE TP53 WILD TYPE | B |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
3 | 24957073 | Detail |
| colorectal cancer |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
B |
Predictive
|
Does Not Support
|
Resistance |
N/A
|
1 | 24146218 | Detail |
| colorectal cancer |
BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 2 | 22180495 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| This Phase III trial took patients with locally ad... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| In this Phase III trial, trastuzumab-based treatme... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| The Clinical Pharmacogenomics Implementation Conso... | DPYD |
DPYD c.1905+1G>A ( ENST00000370192.8 ) DPYD c.1905+1G>A ( ENST00000370192.8 ) |
Adverse Response | true | CIViC Evidence | detail |
| The Clinical Pharmacogenomics Implementation Conso... | DPYD |
DPYD p.Ile560Ser (p.I560S) ( ENST00000370192.8 ) DPYD p.Ile560Ser (p.I560S) ( ENST00000370192.8 ) |
Adverse Response | true | CIViC Evidence | detail |
| The Clinical Pharmacogenomics Implementation Conso... | DPYD | DPYD RS67376798 HOMOZYGOSITY DPYD RS67376798 HOMOZYGOSITY | Adverse Response | true | CIViC Evidence | detail |
| This is Phase II trial of Trastuzumab and capecita... | ERBB2 | ERBB2 OVEREXPRESSION ERBB2 OVEREXPRESSION | Sensitivity | false | CIViC Evidence | detail |
| Case report of a a 58 year old man with multiple b... | ERBB2 | ERBB2 OVEREXPRESSION ERBB2 OVEREXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| In this retrospective biomarker analysis of the EX... | TP53 | TP53 WILD TYPE TP53 WILD TYPE | Sensitivity | true | CIViC Evidence | detail |
| 141 patients were analyzed for ERBB2 (HER2) positi... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| Mouse xenografts using HT29 cells harboring the BR... | BRAF |
BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
Sensitivity | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03818685 | Active, not recruiting | Phase 2 | Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease | July 2, 2019 | May 1, 2024 |
| NCT04942626 | Active, not recruiting | Phase 1 | Capecitabine-based Chemoradiotherapy in Combination With the IL-1 Receptor Antagonist Anakinra for Rectal Cancer Patients | August 20, 2021 | December 31, 2025 |
| NCT04556773 | Active, not recruiting | Phase 1 | A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer | December 17, 2020 | November 28, 2025 |
| NCT02861300 | Active, not recruiting | Phase 1/Phase 2 | CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer | September 12, 2016 | December 2023 |
| NCT03563157 | Active, not recruiting | Phase 1/Phase 2 | QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine | May 25, 2018 | December 30, 2022 |
| NCT01494662 | Active, not recruiting | Phase 2 | HKI-272 for HER2-Positive Breast Cancer and Brain Metastases | February 2012 | December 2024 |
| NCT03377387 | Active, not recruiting | Phase 1/Phase 2 | Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer | December 13, 2017 | December 2024 |
| NCT02344472 | Active, not recruiting | Phase 3 | Detect V / CHEVENDO (Chemo vs. Endo) | September 2015 | January 31, 2025 |
| NCT04940546 | Active, not recruiting | Phase 1/Phase 2 | Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in pMMR/MSS CRLM Patients | June 16, 2021 | October 30, 2024 |
| NCT05063786 | Active, not recruiting | Phase 3 | Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) | September 14, 2021 | November 2024 |
| NCT03371017 | Active, not recruiting | Phase 3 | A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer | January 11, 2018 | June 30, 2024 |
| NCT04072107 | Active, not recruiting | Phase 2 | EPstein-barr Virus DNA Response to Systemic Therapy for Treatment Adaptation in High Risk NPC (EP-STAR) | June 1, 2020 | December 1, 2024 |
| NCT03351296 | Active, not recruiting | Phase 2 | Two Chemotherapy Regimens Plus or Minus Bevacizumab | June 26, 2018 | December 2028 |
| NCT03783442 | Active, not recruiting | Phase 3 | A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma | December 11, 2018 | June 30, 2024 |
| NCT03329248 | Active, not recruiting | Phase 1/Phase 2 | QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | November 6, 2017 | December 2020 |
| NCT02794571 | Active, not recruiting | Phase 1 | Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors | May 23, 2016 | October 5, 2024 |
| NCT01013649 | Active, not recruiting | Phase 3 | Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery | April 5, 2010 | February 13, 2025 |
| NCT02767661 | Active, not recruiting | Phase 3 | Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer | July 19, 2017 | May 2024 |
| NCT04068103 | Active, not recruiting | Phase 2/Phase 3 | Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery | December 16, 2019 | April 30, 2027 |
| NCT04854668 | Active, not recruiting | Phase 3 | A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer | July 30, 2020 | December 31, 2025 |
| NCT03523585 | Active, not recruiting | Phase 3 | DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] | August 1, 2018 | May 1, 2025 |
| NCT04301557 | Active, not recruiting | Phase 2 | PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer | July 31, 2020 | December 30, 2024 |
| NCT04276493 | Active, not recruiting | Phase 1/Phase 2 | Anti-HER2 Bispecific Antibody ZW25 Activity in Combination With Chemotherapy With/Without Tislelizumab | March 26, 2020 | December 31, 2026 |
| NCT03523312 | Active, not recruiting | Phase 2 | Use of High-dose Radiation Therapy Plus Chemotherapy to Improve the Likelihood of Surgical Treatment in Patients With Locally Advanced Pancreatic Cancer | April 30, 2018 | April 2025 |
| NCT02734290 | Active, not recruiting | Phase 1/Phase 2 | Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer | February 23, 2016 | December 2025 |
| NCT03777657 | Active, not recruiting | Phase 3 | Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma | December 13, 2018 | December 31, 2024 |
| NCT04844385 | Active, not recruiting | Phase 2 | Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma | February 20, 2021 | December 20, 2024 |
| NCT05216653 | Active, not recruiting | Phase 2 | Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma (PRECAM) | April 7, 2022 | March 31, 2025 |
| NCT00680901 | Active, not recruiting | Phase 3 | LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib | June 4, 2008 | January 22, 2025 |
| NCT03501979 | Active, not recruiting | Phase 2 | Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD | February 20, 2019 | July 22, 2024 |
| NCT01061515 | Active, not recruiting | Phase 1 | Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer | May 10, 2011 | September 27, 2024 |
| NCT03221426 | Active, not recruiting | Phase 3 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) | October 9, 2017 | June 27, 2025 |
| NCT03153280 | Active, not recruiting | Phase 1 | Dose Escalation Study of Lithium With Oxaliplatin and Capecitabine in Advanced Oesophago-Gastric or Colorectal Cancer | January 13, 2022 | December 2026 |
| NCT04047862 | Active, not recruiting | Phase 1 | Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors | August 26, 2019 | August 2024 |
| NCT02688712 | Active, not recruiting | Phase 2 | ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer | March 24, 2016 | December 2025 |
| NCT04259944 | Active, not recruiting | Phase 2 | Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial | June 16, 2020 | October 15, 2024 |
| NCT02669173 | Active, not recruiting | Phase 1 | Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma | October 11, 2016 | November 1, 2024 |
| NCT01081262 | Active, not recruiting | Phase 3 | Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer | October 12, 2010 | March 1, 2025 |
| NCT04034251 | Active, not recruiting | Phase 2 | Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis | June 9, 2020 | January 30, 2027 |
| NCT04937738 | Active, not recruiting | Phase 2 | Perioperative Chemotherapy in Gastric Cancer | July 21, 2021 | July 1, 2029 |
| NCT03775525 | Active, not recruiting | Phase 1 | Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer | March 1, 2019 | December 2023 |
| NCT05108428 | Active, not recruiting | Early Phase 1 | Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma | December 23, 2021 | October 2026 |
| NCT03500380 | Active, not recruiting | Phase 2/Phase 3 | A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases | April 24, 2018 | December 31, 2024 |
| NCT05833919 | Active, not recruiting | Phase 2 | Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients | July 30, 2018 | July 2023 |
| NCT03756298 | Active, not recruiting | Phase 2 | Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer | January 15, 2019 | January 31, 2027 |
| NCT03117972 | Active, not recruiting | Phase 2 | Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels | August 4, 2017 | December 2025 |
| NCT03487666 | Active, not recruiting | Phase 2 | OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease | May 21, 2018 | December 2022 |
| NCT04721977 | Active, not recruiting | Phase 2 | A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001) | April 8, 2021 | December 6, 2028 |
| NCT02595424 | Active, not recruiting | Phase 2 | Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery | April 6, 2016 | January 1, 2029 |
| NCT03929666 | Active, not recruiting | Phase 2 | A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | August 29, 2019 | October 30, 2026 |
| NCT03734029 | Active, not recruiting | Phase 3 | Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] | December 27, 2018 | October 1, 2025 |
| NCT03675737 | Active, not recruiting | Phase 3 | Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) | November 8, 2018 | March 1, 2025 |
| NCT05009069 | Active, not recruiting | Phase 2 | A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer | March 18, 2022 | October 30, 2026 |
| NCT03653507 | Active, not recruiting | Phase 3 | A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | November 28, 2018 | March 31, 2025 |
| NCT04523818 | Active, not recruiting | Phase 1 | Short-Course Chemoradiotherapy Followed by Chemotherapy for the Treatment of Resectable Gastric Adenocarcinoma | August 11, 2020 | December 31, 2028 |
| NCT04494425 | Active, not recruiting | Phase 3 | Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer | July 24, 2020 | June 19, 2026 |
| NCT01804790 | Active, not recruiting | Phase 3 | Efficacy of Neoadjuvant Folfirinox Regimen in Patients With Resectable Locally Advanced Rectal Cancer | January 2012 | May 2025 |
| NCT05104866 | Active, not recruiting | Phase 3 | A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) | October 18, 2021 | August 15, 2025 |
| NCT04908813 | Active, not recruiting | Phase 2 | Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer | September 29, 2021 | December 2025 |
| NCT05568095 | Active, not recruiting | Phase 3 | A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body | November 21, 2022 | May 2026 |
| NCT01824875 | Active, not recruiting | Phase 2 | Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors | August 8, 2013 | December 2024 |
| NCT01191697 | Active, not recruiting | Phase 2 | CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer | February 2011 | July 2024 |
| NCT03451370 | Active, not recruiting | First-line Combination of Capecitabine and Oxaliplatin Plus Bevacizumab in Elderly Patients With Metastatic Colorectal Cancer | November 1, 2017 | December 2024 | |
| NCT03615326 | Active, not recruiting | Phase 3 | Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) | October 5, 2018 | December 30, 2024 |
| NCT05251948 | Active, not recruiting | Phase 1/Phase 2 | An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma | March 1, 2022 | June 22, 2025 |
| NCT00301925 | Active, not recruiting | Phase 3 | Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By Surgery | December 16, 2005 | September 2024 |
| NCT04250948 | Active, not recruiting | Phase 2 | Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric Cancer | October 12, 2019 | October 5, 2024 |
| NCT03399110 | Active, not recruiting | Phase 3 | XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC) | December 1, 2017 | August 1, 2026 |
| NCT02560298 | Active, not recruiting | Phase 2 | Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer | August 23, 2016 | August 2023 |
| NCT02978612 | Active, not recruiting | Phase 2 | Adjuvant Chemotherapy In Elderly With Colon Cancer Stage III | June 2016 | January 2032 |
| NCT04662710 | Active, not recruiting | Phase 3 | Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015) | December 30, 2020 | February 2, 2026 |
| NCT05239169 | Active, not recruiting | Phase 2 | Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer | May 23, 2022 | June 30, 2025 |
| NCT02973737 | Active, not recruiting | Phase 3 | A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer | July 20, 2016 | June 2023 |
| NCT02514278 | Active, not recruiting | Phase 3 | Optimisation of Response for Organ Preservation in Rectal Cancer : Neoadjuvant Chemotherapy and Radiochemotherapy vs. Radiochemotherapy | January 28, 2016 | June 2024 |
| NCT01918527 | Active, not recruiting | Phase 3 | Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer | September 2013 | February 2025 |
| NCT02955940 | Active, not recruiting | Phase 2 | An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib | November 30, 2016 | December 31, 2024 |
| NCT04661150 | Active, not recruiting | Phase 2 | A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction | March 12, 2021 | August 30, 2026 |
| NCT02505750 | Active, not recruiting | Phase 3 | Safety of a Boost (CXB or EBRT) in Combination With Neoadjuvant Chemoradiotherapy for Early Rectal Adenocarcinoma | June 24, 2015 | June 2030 |
| NCT05064085 | Active, not recruiting | Phase 1 | Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer | October 12, 2021 | September 9, 2025 |
| NCT02872116 | Active, not recruiting | Phase 3 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer | October 12, 2016 | May 31, 2024 |
| NCT01941641 | Active, not recruiting | Phase 2 | Colon Neoadjuvant FOLFOXIRI Study | October 9, 2013 | December 31, 2025 |
| NCT03586869 | Active, not recruiting | Phase 1/Phase 2 | QUILT-3.080: NANT Pancreatic Cancer Vaccine | July 28, 2018 | December 2019 |
| NCT04895358 | Active, not recruiting | Phase 3 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) | June 18, 2021 | July 21, 2028 |
| NCT04158258 | Active, not recruiting | A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America | February 21, 2020 | November 28, 2025 | |
| NCT03585465 | Active, not recruiting | Phase 1/Phase 2 | Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors | March 26, 2019 | January 2028 |
| NCT04595565 | Active, not recruiting | Phase 3 | Sacituzumab Govitecan in Primary HER2-negative Breast Cancer | October 28, 2020 | March 30, 2029 |
| NCT02934529 | Active, not recruiting | Phase 3 | Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab | March 2015 | December 2024 |
| NCT02931890 | Active, not recruiting | Phase 2 | Multicentric Randomised Trial for Resectable Gastric Cancer | December 21, 2017 | March 2029 |
| NCT03387111 | Active, not recruiting | Phase 1/Phase 2 | QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed | January 13, 2018 | April 2021 |
| NCT02445391 | Active, not recruiting | Phase 3 | Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy | October 20, 2015 | March 29, 2031 |
| NCT04156698 | Active, not recruiting | Phase 2 | Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma | May 21, 2020 | January 16, 2026 |
| NCT02419495 | Active, not recruiting | Phase 1 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | June 26, 2015 | December 31, 2024 |
| NCT02009449 | Active, not recruiting | Phase 1 | A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors | November 15, 2013 | August 25, 2024 |
| NCT03869892 | Active, not recruiting | Phase 3 | Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy. | March 21, 2019 | June 30, 2024 |
| NCT05387603 | Active, not recruiting | Phase 3 | Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors. | November 1, 2022 | October 2025 |
| NCT02892123 | Active, not recruiting | Phase 1 | Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers | September 30, 2016 | July 1, 2024 |
| NCT02873195 | Active, not recruiting | Phase 2 | Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer | July 7, 2017 | July 1, 2024 |
| NCT03387085 | Active, not recruiting | Phase 1/Phase 2 | QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. | March 16, 2018 | October 2023 |
| NCT02170090 | Active, not recruiting | Phase 3 | Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer | April 2014 | April 2024 |
| NCT04304209 | Active, not recruiting | Phase 2 | Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer | October 28, 2019 | October 18, 2026 |
| NCT04882241 | Active, not recruiting | Phase 3 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension | July 29, 2020 | June 27, 2025 |
| NCT05144854 | Active, not recruiting | Phase 3 | A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) | November 5, 2021 | May 2027 |
| NCT02288195 | Active, not recruiting | Phase 3 | CONVERT: Neoadjuvant Chemotherapy Alone Versus Preoperative Chemoradiation for Locally Advanced Rectal Cancer Patients | August 13, 2014 | March 2024 |
| NCT03852251 | Active, not recruiting | Phase 1/Phase 2 | A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma | January 18, 2019 | August 31, 2023 |
| NCT04220203 | Approved for marketing | Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer | |||
| NCT00196820 | Completed | Phase 2 | Mono Efficacy of Capecitabine (MoniCa) | July 2005 | December 2008 |
| NCT04534218 | Completed | Phase 2 | Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer | October 16, 2020 | December 13, 2023 |
| NCT00201825 | Completed | Phase 2 | A Phase II Study of Capecitabine and Docetaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer Patients | December 2004 | April 2013 |
| NCT00207129 | Completed | Phase 1 | Effect of Capecitabine on the Pharmacokinetics of BMS-247550 and BMS-247550 on the Pharmacokinetics of Capecitabine and Its Metabolites in Patients With Advanced Malignancies | October 2004 | December 2005 |
| NCT00209092 | Completed | Phase 2 | Randomized Phase II Trial Induction Therapy for Early Stage Breast Cancer | August 2006 | October 2012 |
| NCT00212589 | Completed | Phase 3 | Patients Preference for Oral or i.v. Therapy | December 2002 | April 2004 |
| NCT00215501 | Completed | Phase 1 | Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies | November 2001 | September 2008 |
| NCT00215644 | Completed | Phase 2 | Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer | August 31, 2005 | August 31, 2008 |
| NCT00215982 | Completed | Phase 2 | Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal Cancer | December 2004 | July 2007 |
| NCT00216021 | Completed | Phase 2 | Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer | March 2004 | June 2007 |
| NCT04464174 | Completed | Phase 2 | Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer | October 8, 2020 | November 10, 2023 |
| NCT00217711 | Completed | Phase 1/Phase 2 | Oxaliplatin, Irinotecan, and Capecitabine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Cannot Be Removed By Surgery | May 2005 | October 2011 |
| NCT04456699 | Completed | Phase 3 | Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003) | August 19, 2020 | November 6, 2023 |
| NCT00226980 | Completed | Phase 2 | A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma | October 2002 | July 2006 |
| NCT04366713 | Completed | Phase 2 | A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib | June 30, 2020 | December 28, 2021 |
| NCT00227747 | Completed | Phase 3 | Radiation Therapy and Capecitabine With or Without Oxaliplatin in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Rectal Cancer | November 8, 2005 | July 15, 2013 |
| NCT00230399 | Completed | Phase 2 | Combination Chemotherapy Treatments in Patients With Metastatic Colorectal Cancer | June 2003 | March 2008 |
| NCT04357587 | Completed | Phase 1 | Safety and Feasibility of PD-1 Blockade in the Treatment of dMMR or MSI-H Rectal Cancer | August 6, 2020 | September 25, 2023 |
| NCT00238147 | Completed | Phase 1 | Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Esophageal Cancer | September 2004 | August 2008 |
| NCT00253565 | Completed | Phase 1 | Imatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid Tumors | August 2003 | July 2010 |
| NCT00254137 | Completed | Phase 2 | Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer. | September 2004 | November 2006 |
| NCT00257348 | Completed | Phase 2 | Capecitabine and Docetaxel in Advanced/Recurrent Cervical Cancer | March 2004 | July 2007 |
| NCT00258232 | Completed | Phase 2 | Celecoxib, Capecitabine, and Irinotecan in Treating Patients With Recurrent or Metastatic Colorectal Cancer | January 2002 | August 2007 |
| NCT00258284 | Completed | Phase 2 | Capecitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer | August 2003 | November 2007 |
| NCT00258310 | Completed | Phase 2 | Ph II Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or Chemo | December 2003 | February 2011 |
| NCT00263029 | Completed | Phase 2 | Preoperative Radiotherapy/ Oxaliplatin/ Capecitabine Treatment For Unresectable Locally-advanced Rectal Cancer | June 2002 | |
| NCT00265733 | Completed | Phase 2 | Paclitaxel Poliglumex and Capecitabine in Treating Patients With Metastatic Breast Cancer | February 2006 | May 2013 |
| NCT00266799 | Completed | Phase 3 | The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (P04445/MK-2746-071) | January 13, 2006 | October 18, 2010 |
| NCT00270491 | Completed | Phase 2 | Capecitabine Associated With Weekly Paclitaxel in Metastatic Breast Cancer. | December 2005 | October 2010 |
| NCT00274768 | Completed | Phase 2 | Capecitabine in Treating Patients With Metastatic Breast Cancer | April 2004 | November 2012 |
| NCT00277069 | Completed | Phase 1/Phase 2 | Phase I-II Study of Carboplatin, Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer | May 2000 | March 2006 |
| NCT00278863 | Completed | Phase 2 | Capecitabine Versus S-1 in Elderly Advanced Gastric Cancer (AGC): Randomized Trial | November 2004 | January 2007 |
| NCT00280761 | Completed | Biomarkers in Patients With Rectal Cancer Undergoing Chemotherapy and Radiation Therapy | December 2003 | September 19, 2021 | |
| NCT00281788 | Completed | Phase 1 | Combination Chemotherapy and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer | September 2003 | July 2007 |
| NCT00288002 | Completed | Phase 3 | Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer | January 2005 | |
| NCT00290615 | Completed | Phase 2 | Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery | January 2006 | January 2011 |
| NCT00290693 | Completed | Phase 2 | Capecitabine and Docetaxel in Treating Patients With Recurrent or Progressive Metastatic Pancreatic Cancer | July 2004 | June 2010 |
| NCT00291486 | Completed | Phase 1 | Capecitabine and 131I-huA33 in Patients With Metastatic Colorectal Cancer | October 2003 | August 29, 2012 |
| NCT04258163 | Completed | Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy | January 1, 2019 | July 1, 2019 | |
| NCT00297128 | Completed | Phase 2 | Preoperative Chemoradiation With Capecitabine and Cetuximab | October 2005 | November 2011 |
| NCT00297141 | Completed | Phase 2 | Preoperative Combined Radiochemotherapy for Patients With Rectal Carcinoma | October 2004 | December 2013 |
| NCT00303927 | Completed | Phase 2 | Capecitabine as Second-Line Therapy in Treating Patients With Stage IV Pancreatic Cancer Who Have the Thymidylate Synthase Gene | December 2005 | |
| NCT04247984 | Completed | Phase 2 | A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer | May 1, 2018 | January 31, 2022 |
| NCT00305877 | Completed | Phase 2 | Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By Surgery | February 2006 | February 2012 |
| NCT00309556 | Completed | Phase 3 | Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine in Early Breast Cancer | February 2005 | November 2011 |
| NCT00320749 | Completed | Phase 1 | Capecitabine, Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer | December 2005 | January 2011 |
| NCT00321685 | Completed | Phase 2 | Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer | July 25, 2006 | February 11, 2019 |
| NCT00327743 | Completed | Phase 1/Phase 2 | Combination Study of a New Taxane and Capecitabine in Patients With Metastatic Breast Cancer | August 2006 | March 2009 |
| NCT00337103 | Completed | Phase 3 | E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes | September 20, 2006 | December 11, 2017 |
| NCT00338039 | Completed | Phase 2 | Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients | September 2005 | June 2011 |
| NCT00338988 | Completed | Phase 2 | Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma | August 2003 | May 2009 |
| NCT00345696 | Completed | Phase 2 | 1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR. | June 2006 | January 2011 |
| NCT00345761 | Completed | Phase 1/Phase 2 | Clinical Study of Capecitabine, Oxaliplatin and Bevacizumab in Colorectal Cancer | February 2006 | July 2010 |
| NCT00350961 | Completed | Phase 1/Phase 2 | Gemcitabine, Oxaliplatin and Capecitabine in Patients With Advanced Cholangiocarcinoma | June 2004 | February 2008 |
| NCT04080843 | Completed | Phase 2 | Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients | November 15, 2019 | July 1, 2022 |
| NCT00354887 | Completed | Phase 2 | Capecitabine and Oxaliplatin in Adenocarcinoma of the Small Bowel and Ampulla of Vater | November 2004 | November 2009 |
| NCT00357253 | Completed | Phase 1 | Capecitabine and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Nonmetastatic Brain Stem Glioma or High-Grade Glioma | January 2006 | March 2010 |
| NCT00363584 | Completed | Phase 3 | Capecitabine or Observation After Surgery in Treating Patients With Biliary Tract Cancer | March 2006 | |
| NCT00365417 | Completed | Phase 2 | Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer | August 2006 | November 2009 |
| NCT00372944 | Completed | Phase 2 | AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy | August 2006 | October 2008 |
| NCT00379262 | Completed | Phase 3 | Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma | September 2006 | December 2018 |
| NCT03958721 | Completed | Phase 1 | Capecitabine and Radiotherapy in the Adjuvant Treatment of Resistant Breast Cancer | July 18, 2019 | October 26, 2023 |
| NCT00398320 | Completed | Phase 2 | Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors | November 2006 | October 2012 |
| NCT00398879 | Completed | Phase 2 | Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients | August 2005 | October 2011 |
| NCT00403429 | Completed | Phase 2 | MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer | March 2006 | July 2008 |
| NCT00408564 | Completed | Phase 2 | Cetuximab, Gemcitabine, and Oxaliplatin Followed By Surgery or External-Beam Radiation Therapy and Capecitabine in Treating Patients With Locally Advanced, Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery | January 2006 | April 2013 |
| NCT03916510 | Completed | Phase 1 | Chemoradiation With Enadenotucirev as a Radiosensitiser in Locally Advanced Rectal Cancer | July 1, 2019 | February 24, 2023 |
| NCT00411229 | Completed | Phase 3 | Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer | June 2006 | November 2012 |
| NCT00411762 | Completed | Phase 1/Phase 2 | A Phase I/II, Multi-Center, Open-Label, Dose-Escalation, Safety and Efficacy Study of PHY906 Plus Capecitabine in Patients With Advanced Pancreatic Carcinoma | December 2006 | December 2009 |
| NCT00414271 | Completed | Phase 2 | Neo-adjuvant Chemotherapy in Locally Advanced Gastric Cancer | January 2006 | October 2015 |
| NCT03901339 | Completed | Phase 3 | Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer | May 8, 2019 | October 20, 2023 |
| NCT00416494 | Completed | Phase 2 | Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer | September 2003 | August 2014 |
| NCT00417209 | Completed | Phase 3 | Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen | December 2006 | November 2009 |
| NCT00418028 | Completed | Phase 2/Phase 3 | Standard Versus Continuous Capecitabine in Advanced Breast Cancer | September 2005 | January 2015 |
| NCT00423696 | Completed | Phase 2 | Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery | March 23, 2006 | August 1, 2011 |
| NCT00425360 | Completed | Phase 3 | Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | September 2006 | March 2013 |
| NCT00427713 | Completed | Phase 3 | Capecitabine and Oxaliplatin or Standard Follow-Up Care in Treating Patients Who Have Undergone Surgery for Locally Advanced Rectal Cancer | November 2004 | |
| NCT00429871 | Completed | Phase 3 | Randomized Phase III Trial With Docetaxel Plus Epirubicine Versus Docetaxel Plus Capecitabine for Metastatic Breast Cancer | May 2002 | November 2007 |
| NCT03887130 | Completed | Phase 2 | Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer | March 27, 2007 | April 18, 2013 |
| NCT00431106 | Completed | Phase 3 | Vinorelbine and Gemcitabine Versus Capecitabine in Pretreated Metastatic Breast Cancer | April 2002 | January 2009 |
| NCT00433550 | Completed | Phase 2 | Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer | May 2007 | May 2016 |
| NCT03872388 | Completed | Phase 2 | Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy | January 14, 2019 | October 19, 2023 |
| NCT00435409 | Completed | Phase 3 | A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer | February 2007 | June 2011 |
| NCT03854799 | Completed | Phase 2 | Immunotherapy In Locally Advanced Rectal Cancer | April 1, 2019 | September 30, 2023 |
| NCT00438100 | Completed | Phase 2 | Capecitabine vs. S-1 in Unresectable or Recurrent Breast Cancer | April 2008 | May 2013 |
| NCT00438256 | Completed | Phase 1/Phase 2 | Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer | December 2007 | December 2017 |
| NCT03853707 | Completed | Phase 1/Phase 2 | Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer | March 4, 2019 | September 19, 2023 |
| NCT00444678 | Completed | Phase 2 | Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer | June 1, 2004 | June 1, 2015 |
| NCT00448552 | Completed | Phase 2 | Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer | February 2004 | June 2008 |
| NCT00452673 | Completed | Phase 1 | Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer | June 2007 | October 2012 |
| NCT03802591 | Completed | Phase 3 | A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma | March 28, 2019 | September 22, 2023 |
| NCT00454636 | Completed | Phase 2 | A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer. | March 2007 | July 2010 |
| NCT00468585 | Completed | Phase 1/Phase 2 | Study of Biweekly Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model | June 2005 | April 2011 |
| NCT00469443 | Completed | Phase 3 | Randomized Phase III Study of Folfiri+Avastin Versus Xeliri+Avastin as 1st Line Treatment of CRC | December 2006 | February 2010 |
| NCT00470184 | Completed | Phase 2 | Oxaliplatin, Capecitabine, and Radiation Therapy in Patients Undergoing Surgery for Stage II, III, IV Esophageal Cancer | November 2006 | |
| NCT00477464 | Completed | Phase 2 | Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer | June 2007 | December 2010 |
| NCT03781362 | Completed | Phase 1 | Study of CPI-100 in Patients With Advanced Tumors | December 21, 2018 | June 21, 2022 |
| NCT00480584 | Completed | Phase 1 | A Phase I Trial of Capecitabine in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer | April 2007 | November 2012 |
| NCT00480597 | Completed | Phase 2 | Gemcitabine/Vinorelbine Versus Gemcitabine/Cisplatin Versus Gemcitabine/Capecitabine in Metastatic Breast Cancer | October 2002 | |
| NCT00483366 | Completed | Phase 1 | Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors | August 15, 2006 | March 29, 2011 |
| NCT00483405 | Completed | Phase 2 | Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer | October 2006 | December 2010 |
| NCT00483834 | Completed | Phase 2 | A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer | December 2006 | July 2011 |
| NCT00484939 | Completed | Phase 3 | A Study of Bevacizumab (Avastin) in Combination With Capecitabine (Xeloda) in Elderly Patients With Metastatic Colorectal Cancer | July 2007 | March 2013 |
| NCT00486356 | Completed | Phase 1 | Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer | October 1, 2004 | January 1, 2010 |
| NCT00493636 | Completed | Phase 2 | 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy | June 2007 | November 2012 |
| NCT00496587 | Completed | Phase 2 | Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma | July 2007 | May 2016 |
| NCT03770689 | Completed | Phase 1/Phase 2 | Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer | March 20, 2019 | February 21, 2022 |
| NCT00504660 | Completed | Phase 2 | 6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients | September 2003 | August 2010 |
| NCT03745170 | Completed | Phase 3 | Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer | December 19, 2018 | October 21, 2022 |
| NCT00514761 | Completed | Phase 2 | Phase II Efficacy Study of AZD6244 in Colorectal Cancer | September 2006 | July 2008 |
| NCT00532909 | Completed | Phase 1 | Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer | July 2006 | May 2010 |
| NCT00534417 | Completed | Phase 2 | Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer | October 2007 | September 2011 |
| NCT00536809 | Completed | Phase 1 | Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer | September 26, 2007 | October 31, 2008 |
| NCT03641547 | Completed | Phase 1 | M6620 Plus Standard Treatment in Oesophageal and Other Cancer | December 4, 2018 | April 4, 2022 |
| NCT00540800 | Completed | Phase 3 | BREAST-10: Three-weekly Versus Weekly First-line Chemotherapy for Metastatic or Locally Advanced Breast Cancer | February 2004 | December 2009 |
| NCT00543842 | Completed | Phase 1 | Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer | December 2007 | December 2013 |
| NCT03607656 | Completed | Phase 2/Phase 3 | The Effect of Traditional Chinese Treatment Combined Adjuvant Chemotherapy in IIIb and IIIc Gastric Cancer | June 8, 2018 | November 30, 2023 |
| NCT00547547 | Completed | Phase 1 | High-Selenium Brassica Juncea, Irinotecan, and Capecitabine in Treating Patients With Advanced Cancer | April 2006 | August 2012 |
| NCT00548548 | Completed | Phase 3 | A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer | September 2007 | November 2013 |
| NCT00551096 | Completed | Phase 1 | Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors | October 2007 | May 2013 |
| NCT00551213 | Completed | Phase 2 | A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003) | November 21, 2007 | June 4, 2009 |
| NCT00555620 | Completed | Phase 1 | Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer | May 2008 | December 2011 |
| NCT00559676 | Completed | Phase 4 | Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer | March 2005 | |
| NCT00562718 | Completed | Phase 2 | Capecitabine and Radiation Therapy in Treating Patients With Nonmetastatic Breast Cancer After Surgery | September 2004 | November 2009 |
| NCT00568022 | Completed | Phase 1 | A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer | February 2008 | January 2010 |
| NCT00574171 | Completed | Phase 2 | Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma | September 2007 | August 2009 |
| NCT03578874 | Completed | Phase 2 | SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCC | June 20, 2016 | April 30, 2019 |
| NCT00578071 | Completed | Phase 1/Phase 2 | Phase I/II Study of Panitumumab, Capecitabine and Oxaliplatin w EBRT for Esophageal Cancer | December 2007 | June 2012 |
| NCT00583674 | Completed | Phase 2 | Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma | December 2007 | June 2012 |
| NCT00585078 | Completed | Phase 2 | Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma | May 2004 | December 2011 |
| NCT00601510 | Completed | Phase 1 | Imatinib, Capecitabine, and Cisplatin in Treating Patients With Unresectable or Metastatic Stomach Cancer | November 2007 | January 2012 |
| NCT00601627 | Completed | Phase 2 | Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by Surgery | June 2009 | May 2013 |
| NCT00602082 | Completed | Phase 2 | Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors | August 2005 | December 2009 |
| NCT00604409 | Completed | Phase 1 | Study of Capecitabine in Combination With SIR-Spheres in Patients With Advanced Cancer | April 2006 | January 2015 |
| NCT00609336 | Completed | Phase 2 | Perioperative Therapy for Resectable Pancreatic Cancer | January 2008 | December 2016 |
| NCT00613080 | Completed | Phase 2 | Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer | April 2008 | December 2016 |
| NCT00614653 | Completed | Phase 1 | Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer | January 2008 | July 2016 |
| NCT00623805 | Completed | Phase 3 | A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer | March 2008 | May 2012 |
| NCT00626158 | Completed | Phase 1 | Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers | February 2008 | December 2010 |
| NCT00632489 | Completed | Phase 1 | LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients | May 2008 | July 2011 |
| NCT00634725 | Completed | Phase 3 | Gemcitabine With or Without Capecitabine and/or Radiation Therapy or Gemcitabine With or Without Erlotinib in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery | February 2008 | September 2014 |
| NCT00634751 | Completed | Phase 1/Phase 2 | CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma | February 2008 | July 2010 |
| NCT00640081 | Completed | Phase 2 | Combination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal Cancer | July 2007 | September 2015 |
| NCT00645866 | Completed | Phase 2 | Epirubicin, Docetaxel, and Capecitabine in Treating Women With Stage IIIA or Stage IIIB Breast Cancer | April 2003 | March 2006 |
| NCT03535727 | Completed | Phase 1/Phase 2 | A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer | June 21, 2018 | October 3, 2022 |
| NCT00660426 | Completed | Phase 1 | Study Of Advanced Gastrointestinal Malignancies And Other Solid Tumors | March 2005 | April 2008 |
| NCT00662025 | Completed | Phase 2 | Study Of Sunitinib With Capecitabine In Breast Cancer | April 2008 | May 2012 |
| NCT03518242 | Completed | Phase 1 | Molecular Profile of Breast Cancer in Ugandan Patients With Stage IIB-III Breast Cancer | June 6, 2018 | May 4, 2022 |
| NCT00675012 | Completed | Phase 2 | NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer | December 2007 | May 2013 |
| NCT00678535 | Completed | Phase 3 | Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer | June 2008 | February 2013 |
| NCT00684983 | Completed | Phase 2 | Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer | July 30, 2008 | October 15, 2019 |
| NCT00686166 | Completed | Phase 2 | S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer | February 2009 | March 2018 |
| NCT00697502 | Completed | Phase 1 | Study of Capecitabine In Patients With Solid Tumors | May 2007 | May 2012 |
| NCT00706069 | Completed | Phase 1 | Vinorelbine Oral Plus Capecitabine Combination In Metastatic Breast Cancer | June 2008 | July 2009 |
| NCT00707278 | Completed | Phase 1 | Radiation Therapy and Capecitabine/Oxaliplatin Chemotherapy in the Treatment of Locally Advanced Pancreas Adenocarcinoma | September 2005 | August 2011 |
| NCT00717197 | Completed | Phase 2 | Study of Capecitabine to Treat Recurrent High Grade Gliomas | July 2008 | May 2013 |
| NCT00718913 | Completed | Phase 2 | Postoperative Chemotherapy and Chemo-radiotherapy for Resected Gastric Cancer | April 2008 | September 2009 |
| NCT00719550 | Completed | Phase 1/Phase 2 | AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer | February 2009 | June 2013 |
| NCT00732810 | Completed | Phase 2 | SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716) | July 2008 | June 2011 |
| NCT00741260 | Completed | Phase 1/Phase 2 | Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer | December 9, 2008 | June 2018 |
| NCT03473639 | Completed | Phase 1 | A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy | January 29, 2019 | November 1, 2022 |
| NCT00749450 | Completed | Phase 3 | Combination Chemotherapy After Surgery in Treating Patients With High-Risk Stage II or Stage III Colorectal Cancer | March 2008 | |
| NCT03472365 | Completed | Phase 2 | A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer | April 2, 2018 | November 25, 2020 |
| NCT00766155 | Completed | Phase 3 | Chemotherapy and Radiation Therapy Before Surgery Followed by Capecitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced Rectal Cancer | August 2008 | |
| NCT00777101 | Completed | Phase 2 | Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer | February 4, 2009 | June 3, 2018 |
| NCT00780494 | Completed | Phase 2 | Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma | February 2009 | December 31, 2017 |
| NCT03469557 | Completed | Phase 2 | BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma | July 18, 2017 | August 19, 2020 |
| NCT00789958 | Completed | Phase 2 | S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct | December 2008 | December 2017 |
| NCT00795678 | Completed | Chemotherapeutic Agents in Brain/Breast | September 2008 | April 2013 | |
| NCT00798252 | Completed | Phase 1 | Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers | March 2009 | May 2015 |
| NCT00812864 | Completed | Phase 4 | Pharmacokinetic Study of Capecitabine in Elderly Cancer Patient (≥ 75 Years) | January 2009 | November 2012 |
| NCT00814619 | Completed | Phase 2 | Capecitabine and Radiation Therapy With or Without Panitumumab in Treating Patients With Advanced Rectal Cancer | November 2008 | January 2014 |
| NCT00820222 | Completed | Phase 3 | Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer | April 14, 2009 | March 22, 2018 |
| NCT00828672 | Completed | Phase 2 | Neoadjuvant Bevacizumab, Capecitabine and Radiation Therapy With or Without Oxaliplatin Locally Advanced Rectal Cancer | June 2009 | March 2019 |
| NCT00829166 | Completed | Phase 3 | A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer | February 2009 | September 2015 |
| NCT00842244 | Completed | Phase 1 | Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric Cancer | April 2009 | October 2012 |
| NCT00842491 | Completed | Phase 2 | Study of Endostar With Cisplatin and Capecitabine as 1st Line Treatment in the Advanced Gastric Cancer | November 2008 | December 2010 |
| NCT03396926 | Completed | Phase 2 | Pembrolizumab, Capecitabine, and Bevacizumab in Treating Patients With Microsatellite Stable Colorectal Cancer That Is Locally Advanced, Metastatic, or Cannot Be Removed by Surgery | April 18, 2018 | January 30, 2024 |
| NCT00854477 | Completed | Phase 4 | Pharmacokinetic Study of Adjuvant Capecitabine After Resection of Pancreatic Adenocarcinoma | November 2009 | August 2012 |
| NCT00858429 | Completed | Phase 1 | Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or Liver Metastases | April 1, 2009 | July 8, 2014 |
| NCT00868634 | Completed | Phase 3 | Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast Cancer | February 2009 | October 2015 |
| NCT00869050 | Completed | Phase 2 | Capecitabine and Temozolomide for Neuroendocrine Cancers | August 2005 | October 2014 |
| NCT00869570 | Completed | Phase 1/Phase 2 | External-Beam Radiation Therapy, Capecitabine, and Sorafenib in Treating Patients With Locally Advanced Rectal Cancer | March 2009 | September 2016 |
| NCT00882310 | Completed | Phase 2 | A Study of Gemzar, Taxotere, and Xeloda for Adjuvant Pancreatic Cancer | September 2006 | October 2014 |
| NCT00885066 | Completed | Phase 1 | Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer | May 2008 | October 2009 |
| NCT00887822 | Completed | Phase 3 | A Study of Bevacizumab (Avastin) Versus Placebo in Combination With Capecitabine (Xeloda) and Cisplatin as First-Line Therapy for Advanced Gastric Cancer | March 2009 | August 2014 |
| NCT00891878 | Completed | Phase 2 | Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction | August 2009 | January 2013 |
| NCT00909402 | Completed | Phase 1 | A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas | November 2009 | November 2012 |
| NCT00909987 | Completed | Phase 2 | Study of Neoadjuvant CT With Selective Radiotherapy in Patients With Intermediate-Risk Cancer Rectum | March 2009 | June 2013 |
| NCT00916578 | Completed | Phase 2 | Xeloda (Capecitabine) and External Beam Radiation | June 5, 2009 | June 6, 2017 |
| NCT00920868 | Completed | Phase 1 | XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib | May 2009 | August 2014 |
| NCT00938470 | Completed | Phase 2 | Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction | January 2010 | March 2018 |
| NCT00953537 | Completed | N/A | Predicting Response to Capecitabine in Women With Metastatic Breast Cancer | January 2009 | February 2011 |
| NCT03383679 | Completed | Phase 2 | Study on Androgen Receptor and Triple Negative Breast Cancer | March 14, 2018 | July 20, 2022 |
| NCT00960284 | Completed | Phase 2/Phase 3 | Gemcitabine or Combination Chemotherapy Followed by Chemoradiation for Stage IB, II, or III Pancreatic Cancer | June 2003 | June 2009 |
| NCT00960349 | Completed | Phase 1 | Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients | August 2009 | March 2011 |
| NCT00962312 | Completed | Phase 2 | Lapatinib Ditosylate and Capecitabine in Treating Patients With Metastatic Pancreatic Cancer | January 2009 | |
| NCT00966706 | Completed | Phase 2 | Cisplatin, Capecitabine, Gemcitabine and Epirubicin or Docetaxel for Patients With Stage III or IV Pancreatic Cancer | June 2005 | October 2009 |
| NCT00967031 | Completed | Phase 2 | Lapatinib Ditosylate and Capecitabine in Treating Patients With Stage IV Breast Cancer and Brain Metastases | April 2009 | |
| NCT00972881 | Completed | Phase 1/Phase 2 | Capecitabine, Irinotecan Hydrochloride, Cetuximab, and Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer | April 2009 | December 31, 2016 |
| NCT00983268 | Completed | Phase 1 | Capecitabine, Vorinostat, and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer | October 2009 | February 2013 |
| NCT01013740 | Completed | Phase 2 | Lapatinib in Combination With Vinorelbine | November 25, 2009 | March 1, 2016 |
| NCT03295084 | Completed | Phase 1 | Safety, Tolerability and Pharmacokinetics of Oral Tablet of Irinotecan in Adult Patients With Solid Tumors | July 15, 2015 | October 30, 2018 |
| NCT03231176 | Completed | Phase 2 | Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer | December 19, 2017 | April 13, 2020 |
| NCT01022541 | Completed | Phase 2 | Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Untreated Unresectable Liver-only Metastases From Colorectal Cancer | June 2006 | February 2015 |
| NCT01024504 | Completed | Phase 2 | Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer | March 2006 | March 2010 |
| NCT01026142 | Completed | Phase 3 | A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA) | January 26, 2010 | August 7, 2017 |
| NCT01032057 | Completed | Phase 2 | Gemcitabine, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery | July 2009 | June 2013 |
| NCT01041404 | Completed | Phase 3 | ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer | September 2005 | June 2010 |
| NCT01044433 | Completed | Phase 2 | Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck | October 2009 | March 3, 2017 |
| NCT01048580 | Completed | Phase 1 | Study of Perifosine + Capecitabine for Colon Cancer Patients | October 2009 | October 2011 |
| NCT01060007 | Completed | Phase 2 | Five Fractions of Radiotherapy Followed by Full Dose FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer | November 2009 | September 2014 |
| NCT01077986 | Completed | Phase 1/Phase 2 | Everolimus, Cetuximab and Capecitabine in Patients With Metastatic Pancreatic Cancer | August 2009 | August 2011 |
| NCT03152370 | Completed | Phase 1 | Preoperative Radiotherapy and E7046 in Rectum Cancer | May 17, 2017 | September 30, 2021 |
| NCT01095003 | Completed | Phase 3 | Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer | May 2009 | October 2015 |
| NCT01097018 | Completed | Phase 3 | Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer | April 2010 | April 2012 |
| NCT03146377 | Completed | Phase 2 | Study of Xeloxiri Regimen for Patients With Refractory Metastatic Colorectal Cancer | April 2014 | December 2016 |
| NCT01099527 | Completed | Phase 1/Phase 2 | A Trial of RAD001/Capecitabine in Refractory Gastric Cancer | October 2009 | December 2013 |
| NCT01108107 | Completed | Phase 2 | Neoadjuvant Treatment of Colon Cancer | April 2010 | March 2015 |
| NCT01112826 | Completed | Phase 3 | Efficacy of Capecitabine Metronomic Chemotherapy to Triple-negative Breast Cancer | April 23, 2010 | December 31, 2019 |
| NCT01118377 | Completed | Phase 2 | A Study of Capecitabine (Xeloda®) and Concomitant Radiation Therapy in Children With Newly Diagnosed Brainstem Gliomas | May 2007 | April 2013 |
| NCT01128842 | Completed | Phase 1 | A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor | April 2010 | March 2011 |
| NCT01131078 | Completed | Phase 2 | A Study of Avastin (Bevacizumab) in Combination Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum | June 2005 | November 2012 |
| NCT03111732 | Completed | Phase 2 | Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC) | June 14, 2017 | November 8, 2021 |
| NCT03093870 | Completed | Phase 2/Phase 3 | Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer | July 4, 2017 | April 17, 2020 |
| NCT01150630 | Completed | Phase 2 | Gemcitabine, Cisplatin, Epirubicin, and Capecitabine in Treating Patients With Stage I-II Resectable Pancreatic Cancer | May 2010 | August 2017 |
| NCT03084939 | Completed | Phase 3 | Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer | April 24, 2017 | March 14, 2023 |
| NCT01152710 | Completed | Phase 2 | Capecitabine as Radiosensitising Agent in Neoadjuvant Treatment of Locally Advanced Resectable Rectal Cancer | June 2004 | April 2010 |
| NCT01158274 | Completed | Phase 1 | RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors | June 2010 | |
| NCT03082053 | Completed | Phase 1 | A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours | January 31, 2017 | June 6, 2018 |
| NCT03079427 | Completed | Phase 2 | Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma | May 15, 2017 | November 15, 2022 |
| NCT03006705 | Completed | Phase 3 | Study of Adjuvant ONO-4538 With Resected Gastric Cancer | January 31, 2017 | March 31, 2023 |
| NCT01182142 | Completed | Phase 2 | Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients | September 2007 | August 2010 |
| NCT01193517 | Completed | Phase 1/Phase 2 | Azacitidine and CAPOX in Metastatic Colorectal Cancer | August 2010 | November 2016 |
| NCT01206049 | Completed | Phase 2 | Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations | September 2010 | March 2016 |
| NCT01208103 | Completed | Phase 2 | Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma | May 6, 2011 | March 7, 2018 |
| NCT01213238 | Completed | Phase 1 | Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab | September 30, 2010 | September 26, 2018 |
| NCT01226732 | Completed | Phase 1 | A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors | November 2010 | June 2014 |
| NCT02981342 | Completed | Phase 2 | A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma | January 12, 2017 | November 9, 2018 |
| NCT01234337 | Completed | Phase 3 | Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer | February 21, 2011 | October 20, 2017 |
| NCT01234402 | Completed | Phase 2 | Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients | March 2011 | July 2017 |
| NCT02954536 | Completed | Phase 2 | Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer | November 3, 2016 | March 14, 2023 |
| NCT01268943 | Completed | Phase 1 | Study of Postoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients | November 2010 | January 2014 |
| NCT01273051 | Completed | Phase 2 | Transanal Endoscopic Microsurgery (TEM) After Radiochemotherapy for Rectal Cancer | November 2010 | August 2015 |
| NCT02954055 | Completed | Phase 2 | MEtronomic TrEatment Option in Advanced bReast cAncer | September 13, 2017 | November 23, 2022 |
| NCT02935309 | Completed | Phase 1 | Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma | October 14, 2016 | May 14, 2020 |
| NCT01295086 | Completed | N/A | Taxotere®, Eloxatin® and Xeloda® (TEX) in Combination With Herceptin® as Treatment for HER2 Positive Non-resectable Cancer | March 2011 | January 2018 |
| NCT01298401 | Completed | Phase 1 | Ganitumab and Gemcitabine Hydrochloride Followed by Radiation Therapy, Ganitumab, Capecitabine, and Maintenance Therapy in Treating Patients With Locally Advanced Cancer of the Pancreas | February 2012 | November 2013 |
| NCT01300962 | Completed | Phase 1 | Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer | August 2011 | December 31, 2018 |
| NCT01323530 | Completed | Phase 1/Phase 2 | A Confirmation Study of Eribulin in Combination With Capecitabine | January 26, 2010 | October 13, 2015 |
| NCT01326481 | Completed | Phase 1/Phase 2 | Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer | June 2011 | December 2014 |
| NCT01332604 | Completed | Phase 1 | GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors | July 2011 | June 2015 |
| NCT02921256 | Completed | Phase 2 | Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer | January 11, 2017 | September 20, 2023 |
| NCT01360593 | Completed | Phase 2 | Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma | July 25, 2011 | October 2018 |
| NCT01374425 | Completed | Phase 2 | Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC) | August 2011 | July 2015 |
| NCT01386346 | Completed | Phase 1 | Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer | June 2011 | September 2018 |
| NCT01399190 | Completed | An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer | July 2011 | February 2014 | |
| NCT01423604 | Completed | Phase 2 | Study of Ruxolitinib in Pancreatic Cancer Patients | July 2011 | November 2016 |
| NCT01433614 | Completed | Phase 3 | Epirubicin and Paclitaxel, Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer | December 2002 | December 2013 |
| NCT01439282 | Completed | Phase 2 | Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer | August 2011 | May 2014 |
| NCT01442155 | Completed | An Observational Study of Adjuvant Treatment With Capecitabine (Xeloda) in Combination With Oxaliplatin in Participants With Stage III Colon Cancer | October 2011 | April 2015 | |
| NCT01461057 | Completed | Phase 2 | A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer | December 6, 2011 | October 31, 2017 |
| NCT02864849 | Completed | Phase 2 | Total Neoadjuvant Induction and Consolidation CapeOX Plus IMRT With Capecitabine for MRI Defined High-risk Rectal Cancer | August 2016 | June 2019 |
| NCT02860234 | Completed | Tailored Operative or Non-operative Management for Low-risk Rectal Cancer After Intensive Neoadjuvant Treatment | August 2016 | November 2019 | |
| NCT01497392 | Completed | Phase 1 | Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers | March 29, 2012 | February 7, 2017 |
| NCT01500993 | Completed | Phase 3 | Capecitabine in the Perioperative Treatment of Rectal Cancer | March 2002 | March 2011 |
| NCT01503983 | Completed | Phase 2 | Efficacy and Safety of Trastuzumab, Capecitabine y Oxaliplatine as Treatment Gastric Cancer Metastatic (HER2)Positive | August 2011 | May 2015 |
| NCT01506167 | Completed | An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN) | July 6, 2012 | March 10, 2017 | |
| NCT01517009 | Completed | Phase 2 | A Multicenter Phase II Study of Neoadjuvant Docetaxel, Cisplatin and Capecitabine and Protocolized Surgery in Resectable Gastric Cancer | June 2008 | May 2013 |
| NCT01525082 | Completed | Phase 2 | Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors | December 2012 | December 31, 2019 |
| NCT01530503 | Completed | Phase 2 | Second Line Therapy in Advanced Biliary Tract Cancer | November 2011 | October 2013 |
| NCT01534637 | Completed | Phase 2 | Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer | August 2006 | August 2012 |
| NCT02846428 | Completed | Phase 2 | To Evaluate the Efficacy and Safety of Capecitabine Prior to Surgery in Women With Breast Cancer | March 2004 | December 2011 |
| NCT01558869 | Completed | Phase 2 | Xeloxiri as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma | April 2012 | December 2016 |
| NCT01584544 | Completed | Phase 1 | Safety Study of Capecitabine With Radiation in Elderly Rectal Cancer | January 2011 | May 2014 |
| NCT01588990 | Completed | Phase 4 | A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer | June 26, 2012 | September 30, 2016 |
| NCT01589159 | Completed | Phase 2 | A Phase Ⅱ Study of an All-Oral Combination of Low-dose Etoposide/Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and/or Taxanes | January 2013 | December 2016 |
| NCT01589419 | Completed | Phase 1 | A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer | June 2012 | January 2015 |
| NCT02746796 | Completed | Phase 2/Phase 3 | Study of ONO-4538 in Gastric Cancer | March 2016 | November 17, 2022 |
| NCT02735239 | Completed | Phase 1/Phase 2 | Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer | June 24, 2016 | June 16, 2022 |
| NCT01630083 | Completed | Phase 2 | Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer | July 19, 2012 | January 31, 2019 |
| NCT01634685 | Completed | Phase 1 | A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma | August 8, 2012 | October 6, 2017 |
| NCT01640665 | Completed | Phase 1 | Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors | July 2012 | August 2014 |
| NCT02716766 | Completed | Phase 2 | Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC) | March 2016 | September 2018 |
| NCT01664494 | Completed | An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer, Colon Cancer in the Adjuvant Setting, Advanced Gastric Cancer or Breast Cancer | April 2010 | July 2012 | |
| NCT02715531 | Completed | Phase 1 | A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors | April 6, 2016 | May 31, 2021 |
| NCT01677884 | Completed | Phase 2 | Intra-arterial Hepatic Bevacizumab and Systemic Chemotherapy | November 2012 | February 2016 |
| NCT01696695 | Completed | An Observational Study of First-Line Capecitabine Based Chemotherapy in Participants With Metastatic Colorectal Cancer | July 2011 | December 2014 | |
| NCT02694718 | Completed | Phase 2 | A Study of Capecitabine Plus Oxaliplatin in Combination With Pre-operative Pelvic Radiotherapy in Rectal Cancer | March 2005 | November 2006 |
| NCT01705002 | Completed | Phase 1 | Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors. | October 2012 | June 2018 |
| NCT01710592 | Completed | Phase 2 | A Phase II Trial of Epirubicin, Oxaliplatin and Capecitabine (EOX) Versus Docetaxel and Oxaliplatin (ElTax) in the Treatment of Advanced Gastro-oesophageal Cancer | May 2007 | |
| NCT01711242 | Completed | Phase 2 | Trial of Adjuvant XELOX Chemotherapy and Concurrent Capecitabine and Radiotherapy for Resected Gastric Carcinoma | January 2012 | January 2021 |
| NCT02625610 | Completed | Phase 3 | Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) | December 24, 2015 | June 3, 2021 |
| NCT02614794 | Completed | Phase 2 | A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer | January 28, 2016 | August 11, 2022 |
| NCT01718873 | Completed | Phase 3 | Optimization of Bevacizumab Scheduling With Chemotherapy for Metastatic Colorectal Cancer | May 2012 | December 2019 |
| NCT01722162 | Completed | Phase 2 | Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer | April 2013 | October 2015 |
| NCT01725386 | Completed | An Observational Study of Xeloda (Capecitabine) in Participants With Metastatic or Advanced Breast Cancer | March 2011 | February 2015 | |
| NCT02611960 | Completed | Phase 3 | Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122) | April 18, 2016 | September 30, 2022 |
| NCT01730222 | Completed | Phase 1/Phase 2 | A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma | November 2012 | August 2017 |
| NCT01748773 | Completed | Phase 2 | A Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab With Chemoradiotherapy in the Adjuvant Setting in Operated Participants With Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Gastric or Gastroesophageal Junction Cancer | January 29, 2013 | June 15, 2017 |
| NCT02608073 | Completed | Phase 2 | A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer | November 2004 | November 2009 |
| NCT02581423 | Completed | Phase 4 | A Study of Capecitabine (Xeloda) in the Adjuvant Treatment of Participants With Resected Colon Cancer | August 2005 | March 2007 |
| NCT01774786 | Completed | Phase 3 | A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer | June 10, 2013 | December 31, 2019 |
| NCT01776307 | Completed | Phase 2 | A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer | March 2012 | April 2020 |
| NCT01777945 | Completed | XEBRA Study: An Observational Study of Xeloda (Capecitabine) in Combination With Docetaxel in First Line in Participants With HER2-Negative Metastatic Breast Cancer | December 2012 | December 2014 | |
| NCT01783444 | Completed | Phase 2 | A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. | February 26, 2013 | July 30, 2018 |
| NCT01783756 | Completed | Phase 1/Phase 2 | Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis | June 26, 2013 | May 10, 2019 |
| NCT02576964 | Completed | Phase 2 | A Study of Capecitabine (Xeloda) and Peginterferon Alfa-2a (Pegasys) in Treatment-Naive Participants With Advanced Liver Cancer | January 2005 | November 2008 |
| NCT01808573 | Completed | Phase 3 | A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting | March 29, 2013 | December 9, 2019 |
| NCT01821612 | Completed | Early Phase 1 | Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer | May 2013 | June 15, 2018 |
| NCT02574455 | Completed | Phase 3 | Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) | November 7, 2017 | December 8, 2020 |
| NCT02567331 | Completed | Phase 4 | A Study of Capecitabine (Xeloda) in Patients With Metastatic Colorectal Cancer | October 2004 | April 2006 |
| NCT02565641 | Completed | Phase 2 | A Study of Capecitabine (Xeloda) in Participants With Locally Advanced or Metastatic Pancreatic Cancer | March 2003 | September 2006 |
| NCT01843725 | Completed | Phase 1 | Phase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast Cancers | September 2013 | October 2016 |
| NCT02563054 | Completed | Phase 3 | A Study of Capecitabine (Xeloda) in Participants With Advanced or Metastatic Gastric Cancer | April 2003 | August 2010 |
| NCT01845337 | Completed | Phase 2 | Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine | February 5, 2014 | October 8, 2020 |
| NCT01869192 | Completed | Phase 2 | Phase II Trial for Large ER-Negative Breast Cancers | March 5, 2003 | August 21, 2010 |
| NCT02560974 | Completed | Phase 3 | A Study of Capecitabine (Xeloda) in Combination Chemotherapy Versus Surgery Alone in Participants With Gastric Cancer | June 2006 | November 2012 |
| NCT02558959 | Completed | Phase 2 | Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer | September 1, 2015 | December 31, 2017 |
| NCT01891227 | Completed | Phase 2 | Capecitabine + Bendamustine in Women With Pretreated Locally Advanced or Metastatic Her2-negative Breast Cancer | August 9, 2013 | March 15, 2018 |
| NCT02555657 | Completed | Phase 3 | Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) | October 13, 2015 | November 10, 2020 |
| NCT02551237 | Completed | Phase 3 | Neoadjuvant Treatment for Advanced Rectal Carcinoma | January 7, 2016 | June 2022 |
| NCT01918644 | Completed | Phase 1 | Neoadjuvant SBRT With Concomitant Capecitabine in Resectable Pancreatic Cancer | April 8, 2014 | April 26, 2022 |
| NCT01918852 | Completed | Phase 3 | S-1 Versus Capecitabine in the First Line Treatment of MCC Patients. | December 2013 | March 2018 |
| NCT02494596 | Completed | Phase 1 | A Phase Ib, Open-label, Multicenter Study of the Safety and PK of the Combination of rhuMAb2c4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Capecitabine (Xeloda) in Patients With Advanced Solid Tumors | January 2004 | September 2005 |
| NCT02494583 | Completed | Phase 3 | Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062) | July 31, 2015 | June 6, 2022 |
| NCT01941966 | Completed | Phase 2 | A Study of Substitution of 5-FU (Fluorouracil) by Capecitabine in Scheme of Chemo-radiotherapy in Patients With Squamous Cell Carcinoma of the Anal Canal. | November 2010 | |
| NCT01953003 | Completed | Phase 3 | Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer | September 2013 | July 2017 |
| NCT02483247 | Completed | Phase 1 | A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer | September 2015 | May 2019 |
| NCT02460419 | Completed | Phase 3 | Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma | April 2015 | May 2020 |
| NCT02451553 | Completed | Phase 1 | Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer | November 5, 2015 | April 16, 2022 |
| NCT01996306 | Completed | Phase 3 | A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC | December 2, 2013 | June 30, 2018 |
| NCT01997333 | Completed | Phase 2 | Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer | November 2013 | August 7, 2018 |
| NCT02000882 | Completed | Phase 2 | STAR Cape+BKM120 MBC With Brain Met | May 29, 2014 | March 29, 2019 |
| NCT02004769 | Completed | Phase 2 | Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer | November 2013 | June 2016 |
| NCT02414009 | Completed | Phase 2 | Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients | September 2014 | July 30, 2019 |
| NCT02395640 | Completed | Phase 3 | The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer | March 2015 | February 23, 2021 |
| NCT02394535 | Completed | Phase 1 | Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer | November 12, 2015 | August 31, 2022 |
| NCT02024607 | Completed | Phase 1/Phase 2 | A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer | January 2014 | November 2019 |
| NCT02025192 | Completed | Phase 1 | A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer | December 31, 2013 | March 16, 2020 |
| NCT02393755 | Completed | Phase 1/Phase 2 | Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer | May 8, 2015 | May 18, 2021 |
| NCT02360501 | Completed | Phase 2 | Combination of Docetaxel, Cisplatin, and Capecitabine (DCX) in the Treatment of Nasopharyngeal Carcinoma | January 2008 | April 2016 |
| NCT02028507 | Completed | Phase 3 | Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors | March 13, 2014 | January 11, 2021 |
| NCT02042443 | Completed | Phase 2 | Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery | February 2014 | April 30, 2017 |
| NCT02359058 | Completed | Phase 1 | A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer | February 2015 | November 2016 |
| NCT02358356 | Completed | Phase 2 | Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study | November 2015 | October 31, 2021 |
| NCT02071043 | Completed | Phase 2 | Trial of Xeloda and Oxaliplatin (XELOX) as Neo-adjuvant Chemotherapy Followed by Surgery in Advanced Gastric Cancer Patients With Para-aortic Lymph Node Metastasis | November 2008 | January 2013 |
| NCT02218164 | Completed | Phase 2 | Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma | August 12, 2014 | June 25, 2018 |
| NCT00003867 | Completed | Phase 1 | Irinotecan and Capecitabine in Treating Patients With Solid Tumors | March 1999 | March 2003 |
| NCT00003902 | Completed | Phase 1/Phase 2 | Capecitabine and Vinorelbine in Treating Older Women Who Have Metastatic Breast Cancer With or Without Bone Involvement | March 1999 | September 2005 |
| NCT00004012 | Completed | Phase 2 | Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | December 1998 | December 2000 |
| NCT00004183 | Completed | Phase 2 | Capecitabine in Treating Patients With Malignant Mesothelioma | November 2000 | January 2006 |
| NCT00004187 | Completed | Phase 1/Phase 2 | Capecitabine and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer | June 1999 | April 2004 |
| NCT00005649 | Completed | Phase 2 | Paclitaxel and Capecitabine in Treating Women With Metastatic Breast Cancer | July 1998 | July 4, 2002 |
| NCT00005839 | Completed | Phase 1 | Oxaliplatin Plus Capecitabine in Treating Patients With Metastatic or Recurrent Solid Tumor | August 2000 | June 2004 |
| NCT00006023 | Completed | Phase 2 | Capecitabine in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy | March 2000 | June 2001 |
| NCT00006108 | Completed | Phase 1/Phase 2 | Capecitabine, Paclitaxel, and Trastuzumab in Treating Patients With Metastatic Breast Cancer | August 1999 | July 2002 |
| NCT00006465 | Completed | Phase 1 | Combination Chemotherapy in Treating Patients With Advanced Solid Tumors | December 2000 | April 2005 |
| NCT00003704 | Completed | Phase 1 | Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer | April 1999 | July 2003 |
| NCT00008034 | Completed | Phase 1 | Combination Chemotherapy Before Surgery in Treating Women With Breast Cancer | February 2000 | |
| NCT00010023 | Completed | Phase 1 | Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors | August 2000 | |
| NCT00016926 | Completed | Phase 2 | Capecitabine in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer | April 2001 | |
| NCT00019773 | Completed | Phase 1 | Oxaliplatin Plus Capecitabine in Treating Patients With Colorectal, Appendix, or Small Bowel Cancer | July 1999 | |
| NCT00021047 | Completed | Phase 1/Phase 2 | Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor | July 2001 | June 2004 |
| NCT00022698 | Completed | Phase 2 | Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer | May 2001 | December 2004 |
| NCT00024102 | Completed | Phase 3 | Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer | September 2001 | November 2012 |
| NCT00026234 | Completed | Phase 2 | Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver | February 2002 | |
| NCT06246461 | Completed | N/A | The Therapeutic Effect of Different Doses of Capecitabine | January 1, 2022 | January 22, 2024 |
| NCT00031876 | Completed | Phase 1/Phase 2 | Capecitabine and Paclitaxel in Treating Patients With Metastatic Breast Cancer | May 2000 | September 2004 |
| NCT00032175 | Completed | Phase 3 | Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | April 2002 | May 2007 |
| NCT00033540 | Completed | Phase 2 | S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma | September 2003 | July 2011 |
| NCT00037609 | Completed | Phase 1/Phase 2 | Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients | January 2001 | February 2003 |
| NCT00039390 | Completed | Phase 1 | Gefitinib and Capecitabine in Treating Patients With Advanced Solid Tumors | April 2002 | |
| NCT00039442 | Completed | Phase 2 | Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer | April 29, 2002 | |
| NCT00040859 | Completed | Phase 2 | Oxaliplatin and Capecitabine in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer | September 2002 | April 2008 |
| NCT00042965 | Completed | Phase 2 | Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer | October 2002 | September 2006 |
| NCT00043121 | Completed | Phase 1 | Combination Chemotherapy in Treating Patients With Advanced Cancer That is Metastatic or Cannot Be Removed By Surgery | June 2002 | |
| NCT00047710 | Completed | Phase 1 | Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients With Locally Advanced Pancreatic Cancer | September 2002 | July 2006 |
| NCT05997524 | Completed | Phase 2 | Clinical Efficacy of Trastuzumab in Combination With Capecitabine and Oxaliplatin for the Treatment of HER2-positive Advanced Gastric Cancer. | March 1, 2021 | June 30, 2023 |
| NCT00049335 | Completed | Phase 2 | S0030: Capecitabine in Treating Older Patients W/Metastatic or Recurrent Colorectal Cancer That Cannot Be Surgically Removed | February 2003 | June 2007 |
| NCT00050167 | Completed | Phase 1 | Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer | November 2002 | August 2011 |
| NCT00052273 | Completed | Phase 1 | LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors | December 2002 | October 2005 |
| NCT00054457 | Completed | Phase 2 | Docetaxel and Capecitabine in Treating Patients With Metastatic Cancer of the Stomach or Gastroesophageal Junction | September 2003 | February 2008 |
| NCT00058318 | Completed | Phase 2 | S0312, Gemcitabine and Capecitabine in Treating Patients With Advanced Renal Cell (Kidney) Cancer | December 2004 | November 2008 |
| NCT00062426 | Completed | Phase 3 | Oxaliplatin and Bevacizumab (Avastin™) With Either Fluorouracil and Leucovorin or Capecitabine in Treating Patients With Advanced Colorectal Cancer | May 2003 | February 2011 |
| NCT00064181 | Completed | Phase 3 | Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer | May 2003 | |
| NCT00068588 | Completed | Phase 2 | GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer | October 2003 | March 2010 |
| NCT00069121 | Completed | Phase 3 | A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer | April 18, 2003 | April 21, 2011 |
| NCT00070213 | Completed | Phase 3 | Leucovorin and Fluorouracil With or Without Oxaliplatin Compared to Capecitabine With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer | September 2003 | June 1, 2011 |
| NCT00070252 | Completed | Phase 1/Phase 2 | Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer | September 2003 | June 2010 |
| NCT00074321 | Completed | Phase 1 | Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors | November 2003 | |
| NCT00076609 | Completed | Phase 1/Phase 2 | Study of Botanical PHY906 Plus Capecitabine for Advanced Unresectable Hepatocellular Carcinoma | October 2003 | |
| NCT00077077 | Completed | Phase 1 | DJ-927 and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors | February 2004 | January 2006 |
| NCT00077363 | Completed | Phase 2 | Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer | May 2004 | |
| NCT00078572 | Completed | Phase 3 | Capecitabine (XELODA) With Or Without Lapatinib (GW572016) For Women With Refractory Advanced or Metastatic Breast Cancer | March 2004 | February 2010 |
| NCT00080301 | Completed | Phase 3 | Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer | September 2003 | March 2008 |
| NCT00081796 | Completed | Phase 3 | Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer | April 2004 | September 2006 |
| NCT00082433 | Completed | Phase 3 | Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer | November 2003 | March 2008 |
| NCT00083148 | Completed | Phase 1 | Irinotecan and Capecitabine in Treating Women With Advanced Breast Cancer | November 2002 | September 2006 |
| NCT00084591 | Completed | Phase 1 | Intensity-Modulated Radiation Therapy With Incorporated Boost and Capecitabine Before Surgery in Treating Patients With Locally Advanced Rectal Cancer | December 2003 | February 2007 |
| NCT00084617 | Completed | Phase 2 | Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma | March 2004 | December 2008 |
| NCT00084643 | Completed | Phase 1 | GTI-2040, Oxaliplatin, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer or Other Solid Tumors | May 2004 | |
| NCT00084734 | Completed | Phase 1 | Docetaxel, Capecitabine, and Cisplatin in Treating Patients With Advanced Solid Tumors | May 2002 | December 2009 |
| NCT00084942 | Completed | Phase 2 | Gemcitabine and Capecitabine in Treating Patients With Advanced and/or Inoperable Cholangiocarcinoma or Carcinoma of the Gallbladder | October 2002 | November 2006 |
| NCT00086931 | Completed | Phase 1/Phase 2 | Oxaliplatin, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Rectum | September 2003 | May 2010 |
| NCT00087152 | Completed | Phase 2 | S0338, Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast Cancer | June 2004 | December 2008 |
| NCT00088998 | Completed | Phase 2 | Docetaxel, Capecitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer | December 2004 | December 2010 |
| NCT00093379 | Completed | Phase 2 | Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer | April 2004 | July 2012 |
| NCT00093808 | Completed | Phase 2 | Capecitabine, Vinorelbine, and Trastuzumab in Treating Patients With Metastatic Breast Cancer | August 2004 | May 2013 |
| NCT00095901 | Completed | Phase 2 | Capecitabine For Nasopharyngeal Cancer | June 2004 | May 2007 |
| NCT00100815 | Completed | Phase 2 | Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer | August 2004 | |
| NCT00104689 | Completed | Phase 2 | Capecitabine and Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer | June 30, 2003 | January 2008 |
| NCT00107250 | Completed | Phase 1 | AZD2171 + Chemotherapy in Advanced NSCLC, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07) | January 21, 2005 | January 18, 2011 |
| NCT00107276 | Completed | Phase 2 | S0430 Cyclophosphamide and Capecitabine in Treating Women With Stage IV Breast Cancer | August 2005 | August 2009 |
| NCT00107393 | Completed | Phase 2 | Trastuzumab and Capecitabine in Treating Women With Metastatic Breast Cancer | June 2003 | November 2008 |
| NCT00112918 | Completed | Phase 3 | Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer | December 2004 | June 2012 |
| NCT00113230 | Completed | Phase 2 | Neoadjuvant Chemoradiation With RHUMAB VEGF (Avastin) for Rectal Cancer | February 2005 | January 2009 |
| NCT00114153 | Completed | Phase 1 | Carboplatin, Capecitabine, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer | June 2003 | |
| NCT00114179 | Completed | Phase 2 | Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery | January 2005 | May 2007 |
| NCT00114231 | Completed | Phase 2 | Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer | May 2006 | December 2014 |
| NCT00114816 | Completed | Phase 3 | Docetaxel Followed by CEF (Cyclophosphamide, Epirubicin and 5-Fluorouracil) Compared to Docetaxel and Capecitabine Followed by CEX (Cyclophosphamide, Epirubicin and Capecitabine) as Adjuvant Treatment for Breast Cancer | January 2004 | April 2007 |
| NCT00118755 | Completed | Phase 2 | A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer | July 2005 | |
| NCT00119171 | Completed | Phase 1 | Ispinesib In Combination With Capecitabine In Patients With Solid Tumors | November 2004 | |
| NCT00121134 | Completed | N/A | Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer | June 2005 | May 2011 |
| NCT00121251 | Completed | Phase 1/Phase 2 | Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer | June 3, 2005 | March 14, 2017 |
| NCT00121277 | Completed | Phase 1 | Vorinostat and Capecitabine in Treating Patients With Metastatic or Unresectable Solid Tumors | September 2005 | |
| NCT00121836 | Completed | Phase 4 | A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer | June 2005 | December 2008 |
| NCT00123851 | Completed | Phase 2 | Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer | March 2003 | August 2006 |
| NCT00124566 | Completed | Phase 2 | Study of Irofulven in Patients With Hormone-refractory Prostate Cancer | June 2004 | December 2009 |
| NCT00125021 | Completed | Phase 2 | Tarceva and Capecitabine for Pancreatic Cancer | October 2003 | September 2008 |
| NCT00129935 | Completed | Phase 3 | EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer | February 2004 | April 4, 2019 |
| NCT00130533 | Completed | Phase 3 | Maintenance Treatment With Capecitabine Versus Observation in Breast Cancer Patients | January 2006 | February 17, 2017 |
| NCT00142038 | Completed | Phase 2 | Docetaxel and Capecitabine in Advanced Gastric Cancer | March 2004 | December 2007 |
| NCT00142480 | Completed | Phase 2 | Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer | December 2004 | April 2011 |
| NCT00146588 | Completed | N/A | Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer | April 2002 | December 2004 |
| NCT00148122 | Completed | Phase 2 | A Study of a New Combination and Schedule of Chemotherapy Drugs for the Treatment of Head and Neck Cancer | November 2002 | July 2010 |
| NCT00148876 | Completed | Phase 3 | TBP Study With Capecitabine Plus Minus Trastuzumab | September 2003 | January 2011 |
| NCT00151047 | Completed | Phase 2 | Docetaxel Plus Capecitabine in Newly Diagnosed Localized or Locally Advanced Prostate Cancer | March 2003 | October 2007 |
| NCT00153907 | Completed | Phase 1 | Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer | March 2002 | September 2011 |
| NCT00156312 | Completed | N/A | Evaluation of Tumor Factors in Breast Cancer Treated With Docetaxel and Capecitabine | July 2003 | February 2007 |
| NCT00159432 | Completed | Phase 2 | Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer | February 2005 | March 2013 |
| NCT00165217 | Completed | Phase 2 | Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma | November 2001 | December 2005 |
| NCT00169000 | Completed | Phase 1 | Safety Study of a New Schedule of Capecitabine and Docetaxel to Treat Cancers | January 2003 | March 2006 |
| NCT04720131 | Completed | Phase 2 | Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer. | January 1, 2021 | May 30, 2023 |
| NCT04679597 | Completed | Total Neoadjuvant Therapy Versus Standard Therapy of Locally Advanced Rectal Cancer With High Risk Factors for Failure | January 1, 2016 | December 31, 2019 | |
| NCT00177307 | Completed | Phase 2 | Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer | January 2005 | February 2012 |
| NCT00191152 | Completed | Phase 3 | A Phase III Trial For Patients With Metastatic Breast Cancer | February 2002 | November 2008 |
| NCT00191438 | Completed | Phase 3 | Phase III Study of Gemcitabine Plus a Cytotoxic Agent Versus Two Cytotoxic Agents | October 2002 | March 2007 |
| NCT00193128 | Completed | Phase 1/Phase 2 | Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer | April 2004 | January 2009 |
| NCT00193609 | Completed | Phase 2 | Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site | September 2004 | January 2009 |
| NCT00194727 | Completed | Phase 2 | Weekly Vinorelbine and Oral Capecitabine as Treatment for Stage IV Breast Cancer | May 2002 | March 2011 |
| NCT00194779 | Completed | Phase 2 | Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery | October 2003 | June 2011 |
| NCT02210364 | Completed | Phase 1 | Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC). | April 2013 | October 2016 |
| NCT02280694 | Completed | Phase 2 | Low Dose Metronomic Poly-chemotherapy for Metastatic CRC | January 2015 | December 2019 |
| NCT02253459 | Completed | Phase 3 | Clinical Study of UTD1 Injection in Combination With Capecitabine in Patients With Advanced and Metastatic Breast Cancer | August 2014 | December 15, 2018 |
| NCT02248571 | Completed | Phase 4 | Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab | August 2014 | September 30, 2017 |
| NCT02083653 | Completed | Phase 2 | Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer | March 6, 2014 | April 26, 2017 |
| NCT02114359 | Completed | Phase 3 | Chemotherapy Options for the First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer | February 2014 | February 2020 |
| NCT02338245 | Completed | Phase 2 | Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab | December 29, 2014 | August 25, 2016 |
| NCT02335411 | Completed | Phase 2 | A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059) | February 3, 2015 | July 23, 2021 |
| NCT02119026 | Completed | Phase 2 | Efficacy And Safety Of Xeliri + Avastin Followed By Xelox + Avastin Or Reverse Sequence In Metastatic Colorectal Cancer | February 2011 | August 31, 2017 |
| NCT02314117 | Completed | Phase 3 | A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer | January 20, 2015 | August 14, 2020 |
| NCT02301143 | Completed | Phase 2 | Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC) | April 21, 2015 | April 26, 2018 |
| NCT02291289 | Completed | Phase 2 | A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) | April 17, 2015 | March 24, 2021 |
| NCT02287129 | Completed | Phase 2 | Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction | December 5, 2014 | August 7, 2020 |
| NCT04134897 | Enrolling by invitation | Phase 3 | Neoadjuvant Chemotherapy in Patients With Moderate Risk Mid Rectal Cancer | October 14, 2019 | October 2024 |
| NCT04103697 | Enrolling by invitation | Phase 3 | Neoadjuvant Chemotherapy in Patients With Intermediate Risk Upper and Mid Rectal Cancer | August 1, 2019 | August 2024 |
| NCT04135313 | Enrolling by invitation | Phase 3 | Induction and Consolidation Chemotherapy in Patients With Locally Advanced CRM-positive Rectal Cancer | October 20, 2019 | October 2024 |
| NCT02354612 | No longer available | Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial | |||
| NCT06463548 | Not yet recruiting | N/A | Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma | July 1, 2024 | December 31, 2026 |
| NCT03684863 | Not yet recruiting | Phase 2 | Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy | October 2018 | December 2025 |
| NCT04337658 | Not yet recruiting | Phase 3 | Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer | July 1, 2020 | April 30, 2026 |
| NCT04488159 | Not yet recruiting | Phase 3 | Immunoscore as Decision Guidance for Adjuvant Chemotherapy in Colon Cancer | December 1, 2024 | June 1, 2026 |
| NCT04621370 | Not yet recruiting | Phase 2 | A Trial of Durvalumab (MEDI 4736) in Combination With Extended Neoadjuvant Regimens in Rectal Cancer | December 7, 2020 | December 31, 2025 |
| NCT04663763 | Not yet recruiting | Phase 2 | Neoadjuvant Short-course Radiotherapy Followed by the Combination of Immunotherapy and Chemotherapy in Locally Advanced Rectal Cancer | December 1, 2020 | December 1, 2025 |
| NCT05111444 | Not yet recruiting | Phase 2 | Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | December 31, 2021 | June 30, 2024 |
| NCT05131893 | Not yet recruiting | Neoadjuvant Treatment of Breast Cancer | March 2022 | December 2031 | |
| NCT05296005 | Not yet recruiting | Phase 1 | Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers | May 31, 2022 | December 31, 2024 |
| NCT05314998 | Not yet recruiting | Phase 3 | Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature | June 15, 2024 | September 1, 2031 |
| NCT05344742 | Not yet recruiting | Phase 1 | A Study of Mitoxantrone Hydrochloride Liposome Injection Combination Therapy in Chinese Patients With Advanced Solid Tumors | April 2022 | March 2025 |
| NCT05438706 | Not yet recruiting | Phase 2 | A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer | July 10, 2022 | July 10, 2024 |
| NCT05451719 | Not yet recruiting | Phase 2 | Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy | July 2022 | July 2025 |
| NCT05479240 | Not yet recruiting | Phase 2 | Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer | September 1, 2023 | June 1, 2028 |
| NCT05507112 | Not yet recruiting | Phase 2 | TIME in Immunotherapy Combined With nCRT for Rectal Cancer | September 20, 2022 | December 1, 2029 |
| NCT05585814 | Not yet recruiting | Phase 2 | Preoperative Pembrolizumab Plus Bevacizumab Combined With Chemotherapy in Patients With pMMR/MSS Locally Advanced Colorectal Cancer | October 2022 | October 2025 |
| NCT05608785 | Not yet recruiting | Phase 1/Phase 2 | Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes | January 1, 2023 | October 1, 2024 |
| NCT05717764 | Not yet recruiting | Phase 3 | Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment | February 2023 | September 2027 |
| NCT05720559 | Not yet recruiting | Phase 2 | Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detection | March 1, 2023 | September 1, 2026 |
| NCT05732493 | Not yet recruiting | Phase 2 | Short-course Radiotherapy Combined With Chemotherapy and Pd-1 Inhibitor for Locally Advanced Colon Cancer(TORCH-C) | March 1, 2023 | December 31, 2024 |
| NCT05794750 | Not yet recruiting | Phase 2 | Assess the Efficacy of Radiotherapy and Sequential Chemotherapy and AK104 Before TME Surgery for Local CRC（AK104-IIT-13） | April 24, 2023 | April 24, 2027 |
| NCT05974059 | Not yet recruiting | Phase 2 | Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer | August 1, 2023 | August 1, 2024 |
| NCT05976568 | Not yet recruiting | Phase 2/Phase 3 | A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma | September 1, 2023 | September 1, 2027 |
| NCT06041035 | Not yet recruiting | Phase 1/Phase 2 | A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors | October 2023 | October 2025 |
| NCT06056804 | Not yet recruiting | Phase 2 | Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer | December 1, 2023 | July 1, 2027 |
| NCT06065371 | Not yet recruiting | Phase 1 | Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy | June 2024 | February 2026 |
| NCT06081959 | Not yet recruiting | Phase 3 | A Phase III Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer | November 30, 2023 | December 31, 2027 |
| NCT06110598 | Not yet recruiting | Phase 2 | CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X) | June 1, 2024 | December 31, 2027 |
| NCT06134375 | Not yet recruiting | Phase 1/Phase 2 | A Study of Tetrathiomolybdate (TM) Plus Capecitabine | July 2024 | July 2034 |
| NCT06139211 | Not yet recruiting | Phase 1/Phase 2 | A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors | November 30, 2023 | April 30, 2026 |
| NCT06156761 | Not yet recruiting | N/A | Mitoxantrone Hydrochloride Liposome Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast Cancer | November 28, 2023 | April 2025 |
| NCT06192680 | Not yet recruiting | Phase 2 | Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer | April 1, 2024 | September 30, 2026 |
| NCT06204094 | Not yet recruiting | Phase 2 | Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer | March 1, 2024 | September 1, 2028 |
| NCT06205485 | Not yet recruiting | Phase 3 | Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer | July 31, 2024 | June 30, 2030 |
| NCT06210971 | Not yet recruiting | Phase 2 | Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer | February 1, 2024 | July 1, 2028 |
| NCT06229067 | Not yet recruiting | Phase 2 | Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer | January 19, 2024 | January 19, 2027 |
| NCT06247995 | Not yet recruiting | Phase 1/Phase 2 | A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. | May 16, 2024 | September 9, 2031 |
| NCT06279364 | Not yet recruiting | Phase 3 | A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer | February 2024 | July 2026 |
| NCT06281405 | Not yet recruiting | Phase 2 | CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer | March 1, 2024 | December 31, 2028 |
| NCT06291064 | Not yet recruiting | Phase 2 | Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer | June 2024 | June 2032 |
| NCT06310473 | Not yet recruiting | Phase 2 | Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial | March 2024 | March 2028 |
| NCT06331845 | Not yet recruiting | Phase 2 | Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma | May 1, 2024 | May 1, 2028 |
| NCT06333769 | Not yet recruiting | Phase 2 | A Phase II Multicenter Clinical Study of Improved Short-course Radiotherapy Combined With CAPOX and PD-1 Monoclonal Antibody for Locally Advanced Mid-low Rectal Cancer | June 1, 2024 | December 1, 2026 |
| NCT06368141 | Not yet recruiting | Phase 2 | Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer | May 1, 2024 | April 30, 2026 |
| NCT06374459 | Not yet recruiting | Phase 1/Phase 2 | Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis | July 31, 2024 | November 30, 2031 |
| NCT06382142 | Not yet recruiting | Phase 3 | A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer | May 2024 | May 2026 |
| NCT06387368 | Not yet recruiting | Phase 4 | Clinical Study of Huaier Granule in the Treatment of Unresectable Pancreatic Cancer | May 2024 | August 2028 |
| NCT06390982 | Not yet recruiting | Phase 2 | Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study | May 2024 | December 2028 |
| NCT06393374 | Not yet recruiting | Phase 3 | Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR | May 24, 2024 | December 14, 2037 |
| NCT06423885 | Not yet recruiting | Phase 2 | A Study of BL-M07D1+PD-1 Monoclonal Antibody and BL-M07D1+PD-1 Monoclonal Antibody+Capecitabine in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma | June 2024 | June 2026 |
| NCT06430827 | Not yet recruiting | Phase 2 | Clinical Study of Irinotecan Hydrochloride Liposome Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract Carcinoma | June 30, 2024 | December 31, 2025 |
| NCT06435429 | Not yet recruiting | Phase 3 | A Phase 3, Randomized, Open-label, Controlled Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | July 16, 2024 | April 25, 2031 |
| NCT06446388 | Not yet recruiting | Phase 2 | Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors | June 30, 2024 | December 1, 2027 |
| NCT05382442 | Recruiting | Phase 2 | A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer | July 27, 2022 | December 25, 2026 |
| NCT02598349 | Recruiting | Phase 2 | Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas | April 2016 | October 2040 |
| NCT02678182 | Recruiting | Phase 2 | Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial | February 2015 | June 2027 |
| NCT03011060 | Recruiting | Phase 3 | Sequential Neo-adjuvant Chemotherapy Followed by Capecitabine Vs. Conventional Adjuvant Chemotherapy in Breast Cancer | December 2016 | February 2025 |
| NCT03073785 | Recruiting | Phase 2 | Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer | September 16, 2016 | December 2027 |
| NCT03161522 | Recruiting | Phase 2 | Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer | February 19, 2018 | December 31, 2026 |
| NCT03213002 | Recruiting | Phase 1/Phase 2 | Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM | June 13, 2017 | June 2026 |
| NCT03257163 | Recruiting | Phase 2 | Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer | September 29, 2017 | December 31, 2025 |
| NCT03280407 | Recruiting | Phase 2 | NEOadjuvant Chemotherapy Only Compared With Standard Treatment for Locally Advanced Rectal Cancer | March 1, 2017 | December 31, 2024 |
| NCT03415763 | Recruiting | Phase 3 | Adjuvant Chemotherapy in Patients With Clinical Stage III Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy | November 5, 2018 | December 2025 |
| NCT03424005 | Recruiting | Phase 1/Phase 2 | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer | April 2, 2018 | May 3, 2026 |
| NCT03561740 | Recruiting | Phase 3 | A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients | July 25, 2018 | December 31, 2028 |
| NCT06109779 | Recruiting | Phase 3 | Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) | December 4, 2023 | September 30, 2030 |
| NCT03764553 | Recruiting | Phase 2 | Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer | May 1, 2019 | August 1, 2024 |
| NCT03899155 | Recruiting | Phase 2 | Pan Tumor Rollover Study | August 9, 2019 | August 25, 2029 |
| NCT03907475 | Recruiting | Phase 2 | Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study) | July 16, 2019 | June 1, 2026 |
| NCT03921684 | Recruiting | Phase 2 | Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients | April 2019 | October 2025 |
| NCT03950154 | Recruiting | Phase 3 | Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer | June 1, 2019 | August 1, 2023 |
| NCT04083365 | Recruiting | Phase 2 | Capecitabine Plus Concomitant Radiation Therapy Followed by Durvalumab as Preoperative Treatment in Rectal Cancer | January 1, 2020 | August 31, 2025 |
| NCT04089631 | Recruiting | Phase 3 | Circulating Tumour DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation | June 26, 2020 | June 2026 |
| NCT04119622 | Recruiting | Phase 2 | Toripalimab Combined With Chemotherapy as Neoadjuvant Treatment of Gastric Cancer | October 8, 2019 | October 2024 |
| NCT04135781 | Recruiting | Phase 3 | Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer | March 1, 2020 | October 31, 2024 |
| NCT04166318 | Recruiting | Phase 2 | Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study | January 2, 2020 | December 31, 2029 |
| NCT04198727 | Recruiting | N/A | Study of the Impact of DPD Activity on the Efficacy of Capecitabine | July 20, 2020 | April 2026 |
| NCT04245865 | Recruiting | Phase 2 | Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer | June 26, 2020 | October 2024 |
| NCT04248452 | Recruiting | Phase 3 | Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body | May 26, 2020 | March 31, 2028 |
| NCT04262687 | Recruiting | Phase 2 | Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate | April 6, 2021 | September 30, 2024 |
| NCT04304352 | Recruiting | Phase 2 | Metronomic Oral Chemotherapy With Cyclophosphamide, Capecitabine and Vinorelbine in Metastatic Breast Cancer Patients | July 29, 2011 | December 31, 2023 |
| NCT04310176 | Recruiting | Phase 2 | Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer | May 24, 2019 | November 2024 |
| NCT04333706 | Recruiting | Phase 1/Phase 2 | A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER) | September 26, 2020 | November 3, 2026 |
| NCT04355858 | Recruiting | Phase 2 | Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer | May 1, 2020 | April 1, 2025 |
| NCT04371224 | Recruiting | Phase 2 | NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer | June 23, 2020 | December 31, 2025 |
| NCT04379596 | Recruiting | Phase 2 | Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) | June 3, 2020 | July 30, 2026 |
| NCT04401709 | Recruiting | Phase 3 | Gemcitabine+ Capecitabine Vs Capecitabine in Curatively Resected Biliary Tract Cancer | April 1, 2021 | March 30, 2025 |
| NCT04428151 | Recruiting | Phase 2 | Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) | August 6, 2020 | February 17, 2027 |
| NCT04430738 | Recruiting | Phase 1/Phase 2 | Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers | September 15, 2020 | October 31, 2025 |
| NCT04443348 | Recruiting | Phase 2 | Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) | December 16, 2020 | December 2024 |
| NCT06112379 | Recruiting | Phase 3 | A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer | November 14, 2023 | August 28, 2030 |
| NCT04495296 | Recruiting | Phase 1/Phase 2 | A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors | August 13, 2020 | November 1, 2024 |
| NCT04501523 | Recruiting | Phase 2 | A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC | August 3, 2020 | August 2032 |
| NCT04518280 | Recruiting | Phase 2 | Short-course Radiotherapy Based TNT Combined With PD-1 Inhibitor for Locally Advanced Rectal Cancer | May 1, 2021 | December 31, 2025 |
| NCT04522284 | Recruiting | Phase 1/Phase 2 | PRECISE CURATE.AI Pilot Clinical Trial | August 20, 2020 | August 1, 2023 |
| NCT04539808 | Recruiting | Phase 2 | NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer | May 27, 2021 | October 5, 2025 |
| NCT04564898 | Recruiting | Phase 1/Phase 2 | Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients. | January 25, 2022 | March 2025 |
| NCT04566380 | Recruiting | Phase 2 | ONO-4538 Phase II Rollover Study (ONO-4538-98) | September 10, 2020 | December 31, 2026 |
| NCT04607421 | Recruiting | Phase 3 | A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer | December 21, 2020 | November 15, 2026 |
| NCT04615013 | Recruiting | Phase 1 | NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer | November 23, 2020 | October 31, 2025 |
| NCT06118333 | Recruiting | Phase 3 | A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma | December 4, 2023 | December 2025 |
| NCT06124378 | Recruiting | Phase 2 | Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer | November 13, 2023 | November 30, 2026 |
| NCT04664829 | Recruiting | Phase 1 | The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC | October 1, 2020 | September 30, 2025 |
| NCT04681911 | Recruiting | Phase 2 | Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer | September 9, 2020 | September 9, 2024 |
| NCT04696757 | Recruiting | Early Phase 1 | Non-OpeRative MANagement of Rectal Cancer Patients | February 1, 2018 | December 31, 2024 |
| NCT04703101 | Recruiting | Phase 1 | Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer | February 11, 2021 | October 15, 2026 |
| NCT04753879 | Recruiting | Phase 2 | Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. | September 29, 2021 | December 1, 2029 |
| NCT04768426 | Recruiting | Phase 2 | Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer | February 3, 2021 | February 2026 |
| NCT04782804 | Recruiting | Phase 1/Phase 2 | Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence | January 1, 2021 | May 1, 2024 |
| NCT04787354 | Recruiting | Phase 3 | Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX) | November 1, 2021 | December 31, 2027 |
| NCT04789096 | Recruiting | Phase 2 | Tucatinib Together With Pembrolizumab and Trastuzumab | March 7, 2023 | September 2025 |
| NCT04803539 | Recruiting | Phase 2/Phase 3 | A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC | April 1, 2021 | September 1, 2033 |
| NCT04808323 | Recruiting | Phase 1 | MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer | June 17, 2021 | June 2026 |
| NCT04849364 | Recruiting | Phase 2 | Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer | August 24, 2021 | January 31, 2034 |
| NCT04856761 | Recruiting | A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection | November 1, 2020 | December 30, 2024 | |
| NCT04864067 | Recruiting | Phase 2 | No Operation After Short Course Radiotherapy Followed By Consolidation Chemotherapy In Locally Advanced Rectal Cancer | June 9, 2021 | May 30, 2025 |
| NCT04894643 | Recruiting | N/A | Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer | September 14, 2020 | December 31, 2026 |
| NCT04929028 | Recruiting | Phase 2 | Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer | August 9, 2022 | September 15, 2029 |
| NCT04997837 | Recruiting | Phase 3 | Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma | July 21, 2021 | October 21, 2027 |
| NCT05002686 | Recruiting | Phase 2/Phase 3 | Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node Metastasis | August 7, 2021 | August 1, 2024 |
| NCT05007106 | Recruiting | Phase 2 | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) | September 16, 2021 | February 22, 2027 |
| NCT05040360 | Recruiting | Phase 2 | Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors | May 5, 2022 | March 31, 2025 |
| NCT05044117 | Recruiting | Phase 3 | Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN) | October 18, 2021 | October 2026 |
| NCT05062317 | Recruiting | Phase 2 | ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases | April 26, 2022 | February 28, 2026 |
| NCT05062889 | Recruiting | Phase 2 | Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients | May 17, 2023 | December 2027 |
| NCT05093907 | Recruiting | Phase 1/Phase 2 | A Study to Evaluate Safety and Efficacy of BEY1107 in Combination With Capecitabine in Patients With Metastatic Colorectal Cancer | August 31, 2021 | July 31, 2024 |
| NCT06281886 | Recruiting | Phase 2 | Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma | December 1, 2023 | December 1, 2026 |
| NCT06282445 | Recruiting | Phase 2 | Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer | March 1, 2024 | March 31, 2026 |
| NCT05136326 | Recruiting | Phase 2 | Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer | December 1, 2021 | December 2026 |
| NCT05152147 | Recruiting | Phase 3 | A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers | December 2, 2021 | February 1, 2026 |
| NCT05177133 | Recruiting | Phase 2 | Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus) | November 5, 2021 | November 4, 2029 |
| NCT05201859 | Recruiting | Phase 2 | Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma | March 29, 2022 | February 15, 2026 |
| NCT05212454 | Recruiting | Phase 3 | Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks | March 15, 2023 | December 2029 |
| NCT05236972 | Recruiting | Phase 3 | PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer | January 1, 2022 | December 31, 2028 |
| NCT05247905 | Recruiting | Phase 2 | Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors | March 16, 2022 | October 2033 |
| NCT05249101 | Recruiting | Phase 1/Phase 2 | A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma | August 15, 2022 | April 2025 |
| NCT05288777 | Recruiting | Phase 2/Phase 3 | Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer | July 11, 2022 | October 2026 |
| NCT05290194 | Recruiting | Phase 2 | Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma | March 28, 2022 | January 1, 2027 |
| NCT06155383 | Recruiting | Phase 2 | Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma. | November 27, 2023 | December 31, 2027 |
| NCT05307198 | Recruiting | Phase 2 | Rectal Artery Infusion Chemotherapy Combined With Anti-PD1 Antibody for MSS LARC | May 11, 2022 | April 25, 2025 |
| NCT06417476 | Recruiting | Phase 2 | Short-course Radiotherapy or Long-course Chemoradiation Followed by mFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer | December 12, 2022 | December 2025 |
| NCT05336721 | Recruiting | Phase 2 | A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC | November 5, 2021 | August 9, 2024 |
| NCT05342792 | Recruiting | Phase 3 | Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma | April 17, 2022 | June 2029 |
| NCT06169202 | Recruiting | A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients | June 1, 2023 | June 2025 | |
| NCT05374512 | Recruiting | Phase 3 | A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02) | May 16, 2022 | December 3, 2025 |
| NCT05390476 | Recruiting | Phase 2 | Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial | August 1, 2022 | December 1, 2024 |
| NCT05411380 | Recruiting | Phase 2 | Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor. | October 3, 2022 | April 1, 2025 |
| NCT05412082 | Recruiting | Phase 1 | SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer | October 5, 2022 | October 2027 |
| NCT05417386 | Recruiting | Phase 1 | FOLFIRINOX + NIS793 in Pancreatic Cancer | August 9, 2022 | May 1, 2025 |
| NCT06177041 | Recruiting | Phase 3 | M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma. | December 25, 2023 | April 11, 2027 |
| NCT06451211 | Recruiting | Phase 2 | Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer | May 17, 2023 | November 2027 |
| NCT05464030 | Recruiting | Phase 1 | Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) | August 4, 2022 | February 27, 2026 |
| NCT05472948 | Recruiting | Phase 2 | Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma | February 1, 2023 | November 30, 2025 |
| NCT06312176 | Recruiting | Phase 3 | A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) | April 14, 2024 | April 12, 2031 |
| NCT05482893 | Recruiting | Phase 1/Phase 2 | PT886 For Treatment of Patients With Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study) | March 15, 2023 | April 2026 |
| NCT05489211 | Recruiting | Phase 2 | Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) | September 6, 2022 | August 19, 2026 |
| NCT05494190 | Recruiting | N/A | The Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma | November 1, 2022 | November 2025 |
| NCT05498766 | Recruiting | Effect and Safety of Adjuvant Huaier Granule Versus Standard Chemotherapy Regimens in Gastric Cancer Patients | October 12, 2023 | June 30, 2028 | |
| NCT06328738 | Recruiting | Phase 1 | ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer | June 1, 2024 | July 2028 |
| NCT05536102 | Recruiting | Phase 2 | The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy) | September 5, 2022 | September 30, 2027 |
| NCT05555888 | Recruiting | Phase 2 | The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Early Rectal Cancer (TORCH-E） | December 12, 2022 | November 1, 2025 |
| NCT05566743 | Recruiting | Phase 2 | A Study Evaluating Maintenance Therapy After First Line Chemotherapy in Metastatic Cancer Pancreas | September 11, 2022 | September 11, 2024 |
| NCT06206733 | Recruiting | Phase 3 | ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma | January 25, 2024 | December 30, 2028 |
| NCT06455124 | Recruiting | Phase 2 | Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE) | May 8, 2024 | December 30, 2029 |
| NCT05609370 | Recruiting | Phase 1/Phase 2 | A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer | January 29, 2023 | April 2028 |
| NCT05610163 | Recruiting | Phase 2 | Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation | December 8, 2022 | September 2032 |
| NCT05625412 | Recruiting | Phase 1 | A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors | December 9, 2022 | July 30, 2027 |
| NCT05628038 | Recruiting | Phase 2 | The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer | August 18, 2022 | December 1, 2025 |
| NCT05629585 | Recruiting | Phase 3 | A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) | November 28, 2022 | March 27, 2030 |
| NCT05633654 | Recruiting | Phase 3 | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63) | December 12, 2022 | August 2031 |
| NCT05693766 | Recruiting | Phase 2 | Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort | September 11, 2023 | August 31, 2037 |
| NCT05700084 | Recruiting | Phase 1 | Tolerability and Bioavailability of Utidelone Capsule in Patients With Advanced Solid Tumors | June 9, 2023 | April 9, 2025 |
| NCT05702229 | Recruiting | Phase 2 | Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | January 16, 2023 | March 31, 2026 |
| NCT06217185 | Recruiting | Phase 4 | The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC). | January 2, 2024 | June 30, 2027 |
| NCT06332079 | Recruiting | Phase 2 | Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients | March 13, 2024 | February 2027 |
| NCT05731726 | Recruiting | Phase 2 | Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer | February 22, 2023 | February 20, 2025 |
| NCT06239727 | Recruiting | Phase 3 | Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response | March 1, 2024 | February 20, 2030 |
| NCT05775900 | Recruiting | Phase 1/Phase 2 | Efficacy and Safety of Triweekly Cetuximab in Combination With Capecitabine as First-line Maintenance Treatment for KRAS/BRAF Wild-type Metastatic Colorectal Cancer | February 1, 2023 | December 31, 2024 |
| NCT06245889 | Recruiting | Phase 2 | PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC | May 1, 2024 | June 2030 |
| NCT05797077 | Recruiting | Phase 3 | Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA | February 20, 2023 | February 20, 2031 |
| NCT05799820 | Recruiting | Phase 2 | QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC | September 29, 2022 | September 30, 2025 |
| NCT05803382 | Recruiting | Phase 1 | Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers | November 8, 2023 | June 30, 2026 |
| NCT05815303 | Recruiting | Phase 2 | XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal Cancer | March 29, 2023 | March 2026 |
| NCT05821556 | Recruiting | Phase 2 | Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients | June 12, 2023 | June 2026 |
| NCT05836584 | Recruiting | Phase 2 | Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer | December 6, 2023 | October 31, 2027 |
| NCT05838391 | Recruiting | N/A | Adaptive Radiation in Anal Cancer | May 18, 2023 | December 31, 2028 |
| NCT05840211 | Recruiting | Phase 3 | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy | May 8, 2023 | December 2028 |
| NCT05849480 | Recruiting | Phase 1/Phase 2 | A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC) | May 8, 2024 | June 1, 2042 |
| NCT05859477 | Recruiting | Phase 2 | Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer | June 5, 2022 | December 1, 2024 |
| NCT05867121 | Recruiting | Phase 1 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors | October 2, 2023 | December 30, 2025 |
| NCT05877573 | Recruiting | N/A | Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced，High-Risk，MSS Rectal Cancer | July 1, 2023 | August 1, 2026 |
| NCT05902533 | Recruiting | Phase 2/Phase 3 | REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation | August 14, 2023 | August 14, 2029 |
| NCT05912075 | Recruiting | Phase 1 | Preoperative Radiotherapy And ASTX660 in Rectum Cancer | December 19, 2023 | January 2029 |
| NCT05914389 | Recruiting | Phase 2 | Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer | August 2023 | August 2030 |
| NCT05972655 | Recruiting | Phase 2 | Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer | August 2, 2023 | May 1, 2026 |
| NCT06462053 | Recruiting | Phase 2 | Short-course Radiotherapy Combined With CAPOX and PD-1 Antibody Versus Long-course Chemoradiotherapy Combined With CAPOX for Early Low-lying Rectal Cancer | April 1, 2024 | March 1, 2027 |
| NCT05980481 | Recruiting | Phase 2/Phase 3 | A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer | August 4, 2023 | July 10, 2025 |
| NCT05980689 | Recruiting | Phase 2 | Combination of AK104 and Neoadjuvant Chemoradiotherapy in pMMR/MSS Locally Advanced Rectal Cancer | October 24, 2023 | January 31, 2025 |
| NCT06016387 | Recruiting | Phase 2 | Tucatinib With Brain and/or Spinal XRT in Patients With HER2+ Metastatic Breast Cancer and LMD | November 25, 2023 | October 5, 2028 |
| NCT06017583 | Recruiting | Phase 3 | Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal Cancer | September 1, 2023 | August 31, 2026 |
| NCT06018337 | Recruiting | Phase 3 | A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) | January 18, 2024 | May 2028 |
| NCT06037980 | Recruiting | Phase 2/Phase 3 | CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence | November 7, 2023 | January 2029 |
| NCT06256328 | Recruiting | Phase 2 | A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) | December 6, 2023 | December 31, 2027 |
| NCT06266832 | Recruiting | Phase 2 | The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma | January 1, 2024 | December 31, 2027 |
| NCT06268652 | Recruiting | Phase 3 | Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer | January 15, 2024 | January 15, 2028 |
| NCT06343948 | Recruiting | Phase 3 | A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer | April 24, 2024 | May 2026 |
| NCT06085742 | Recruiting | Phase 2 | BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer | November 22, 2023 | September 2034 |
| NCT06102824 | Recruiting | Phase 2 | Organoid-based Functional Precision Therapy for Advanced Breast Cancer | January 20, 2024 | June 30, 2028 |
| NCT01917552 | Recruiting | Phase 3 | Adjuvant Capecitabine Versus Observation Alone in Curatively Resected Stage IB Gastric Cancer((KCSG ST14-05): CATALYSIS | August 19, 2013 | August 1, 2026 |
| NCT01898104 | Recruiting | Phase 1/Phase 2 | Preoperative Valproic Acid and Radiation Therapy for Rectal Cancer | May 2012 | April 2024 |
| NCT02121405 | Suspended | Phase 3 | Randomized Trial of Primary Surgery Followed Selective Radiochemotherapy for Rectal Cancer With MRI Negative CRM | October 2015 | February 2026 |
| NCT05265208 | Suspended | Phase 2 | Selective Internal Radiation Therapy and Capecitabine (Chemotherapy) Treatment for Liver Cancer | February 4, 2022 | February 4, 2030 |
| NCT02897050 | Suspended | Phase 2 | Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer | September 2016 | September 2024 |
| NCT00473005 | Terminated | Phase 1 | Phase I Oral mTOR Inhibitor RAD001 in Combo w/ Capecitabine for Metastatic Breast | August 2007 | December 2011 |
| NCT00148720 | Terminated | Phase 2 | Capecitabine in Women With Operable Breast Cancer | September 2004 | |
| NCT00148135 | Terminated | Phase 2 | Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site | May 2001 | October 2007 |
| NCT02294786 | Terminated | Phase 2 | Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer | December 17, 2014 | October 19, 2017 |
| NCT00717990 | Terminated | Phase 2 | Irinotecan, Capecitabine and Avastin for Metastatic Colorectal Cancer as Salvage Treatment | April 2008 | December 2012 |
| NCT02297230 | Terminated | Phase 1/Phase 2 | Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics | June 2002 | December 2, 2014 |
| NCT00130936 | Terminated | Phase 1/Phase 2 | Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates | October 2005 | November 2007 |
| NCT05648006 | Terminated | Phase 2 | First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer | October 17, 2023 | April 15, 2024 |
| NCT00130507 | Terminated | Phase 2 | Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab | November 4, 2005 | July 25, 2009 |
| NCT04274933 | Terminated | Phase 1 | A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy | May 21, 2020 | October 8, 2020 |
| NCT02120417 | Terminated | Phase 2 | A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer | May 2014 | January 2017 |
| NCT04933227 | Terminated | Phase 2 | A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ) | August 6, 2021 | November 17, 2023 |
| NCT00745134 | Terminated | Phase 2 | Radiation Therapy and Capecitabine With or Without Curcumin Before Surgery in Treating Patients With Rectal Cancer | August 11, 2008 | November 11, 2022 |
| NCT00755534 | Terminated | Phase 2 | Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC | November 2008 | November 2008 |
| NCT00787787 | Terminated | Phase 2 | Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer | September 2008 | June 2010 |
| NCT00268463 | Terminated | Phase 3 | Oxaliplatin and Capecitabine With or Without an Hepatic Arterial Infusion With Floxuridine in Treating Patients Who Are Undergoing Surgery and/or Ablation for Liver Metastases Due to Colorectal Cancer | January 2006 | June 2008 |
| NCT02119663 | Terminated | Phase 3 | A Study of Ruxolitinib in Pancreatic Cancer Patients | June 2014 | October 2016 |
| NCT00049660 | Terminated | Phase 2/Phase 3 | Capecitabine Compared With Vinorelbine in Treating Women With Metastatic Breast Cancer | September 2002 | |
| NCT02117479 | Terminated | Phase 3 | Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1) | March 2014 | December 2016 |
| NCT00107315 | Terminated | Phase 2 | Bevacizumab and Capecitabine as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer | July 2004 | |
| NCT03930771 | Terminated | Phase 2 | Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas | May 21, 2019 | October 1, 2021 |
| NCT00658593 | Terminated | Phase 3 | Gemcitabine With/Out Capecitabine in Locally Advanced, Unresectable, or Metastatic Biliary Cancer | October 10, 2008 | January 18, 2011 |
| NCT05163223 | Terminated | Phase 2 | Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer | February 28, 2022 | May 31, 2024 |
| NCT00268151 | Terminated | Phase 1 | Oxaliplatin in Combination With Capecitabine and Concurrent Radiation Therapy in Non-Small Cell Lung Cancer | February 2005 | |
| NCT02352831 | Terminated | Phase 1/Phase 2 | Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma | August 31, 2015 | October 19, 2018 |
| NCT00101075 | Terminated | Phase 2 | Title XELOX FOR SALIVARY GLAND CANCERS | October 2004 | March 2008 |
| NCT00848783 | Terminated | Phase 2 | Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers | May 2008 | September 2012 |
| NCT00665457 | Terminated | Phase 2 | Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery | April 15, 2004 | July 31, 2009 |
| NCT00256321 | Terminated | Phase 2 | Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction Carcinoma | October 2004 | August 2007 |
| NCT01843452 | Terminated | Phase 2 | Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal | December 2012 | May 2016 |
| NCT01836432 | Terminated | Phase 3 | Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer | May 2013 | March 24, 2017 |
| NCT01823679 | Terminated | Phase 2 | Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin | March 2013 | May 2014 |
| NCT01993472 | Terminated | Phase 2 | Study of Andrographolides With or Without Capecitabine to Treat Colorectal Cancer | November 2013 | December 2016 |
| NCT01765582 | Terminated | Phase 2 | Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer | January 23, 2013 | March 14, 2016 |
| NCT00871273 | Terminated | Phase 4 | Pharmacokinetic Study of Capecitabine After Total Gastrectomy for Stomach Adenocarcinoma | November 2009 | October 2014 |
| NCT00437294 | Terminated | Phase 2 | Enzastaurin in Combination of Capecitabine to Treat Breast Cancer | March 2007 | March 2009 |
| NCT03858972 | Terminated | Phase 2 | Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC | February 5, 2019 | June 11, 2021 |
| NCT01759238 | Terminated | Phase 2 | Chemoradiotherapy for Patients With Oligometastatic Colorectal Cancer | May 2013 | October 2014 |
| NCT00437073 | Terminated | Phase 2 | Brain Metastases In ErbB2-Positive Breast Cancer | May 2007 | February 2010 |
| NCT05091528 | Terminated | Phase 1/Phase 2 | A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers | February 8, 2022 | July 7, 2022 |
| NCT00006812 | Terminated | Phase 2 | Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer | March 2001 | |
| NCT01754623 | Terminated | Phase 2 | GTX-RT in Borderline Resectable Pancreatic Cancer | February 2013 | October 2014 |
| NCT01729923 | Terminated | Phase 2 | A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer | March 2013 | September 6, 2016 |
| NCT01718808 | Terminated | Phase 2 | Cetuximab for Elderly Patients With mCRC | November 2012 | January 2017 |
| NCT03515941 | Terminated | Early Phase 1 | Postoperative Chemoradiation or Chemotherapy After Preoperative Chemotherapy for Gastric Cancers | June 22, 2018 | June 18, 2020 |
| NCT02465593 | Terminated | Phase 1/Phase 2 | A Study of PEP503(Radio-enhancer) With Radiotherapy and Chemotherapy for Patients With Rectal Cancer | June 2015 | July 28, 2021 |
| NCT00235235 | Terminated | A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer | September 2005 | December 2010 | |
| NCT00227656 | Terminated | Phase 2 | Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer | September 2005 | November 2006 |
| NCT01705106 | Terminated | Phase 1 | Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies | August 29, 2012 | February 10, 2016 |
| NCT02076594 | Terminated | Phase 3 | Low-Tox Vs Eox In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer | January 2013 | December 31, 2018 |
| NCT01702558 | Terminated | Phase 2 | A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC) | December 3, 2012 | May 31, 2017 |
| NCT01697072 | Terminated | Phase 3 | First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma | October 2012 | August 2015 |
| NCT01665274 | Terminated | Phase 2 | Efficiency of XELOX Neoadjuvant Chemotherapy in Gastric Cancer | September 2013 | September 2022 |
| NCT01655992 | Terminated | Phase 3 | A Trial Comparing S1 Generic With Capecitabine in Metastatic Breast Cancer (MBC) | January 2012 | October 2017 |
| NCT02726399 | Terminated | Phase 2 | Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer | March 18, 2016 | February 26, 2019 |
| NCT01611506 | Terminated | Phase 1/Phase 2 | Combination Chemotherapy, Cetuximab and Radiation for Patients With Localized Gastric Cancer | February 2012 | December 2012 |
| NCT02473094 | Terminated | Phase 2 | Neoadjuvant Metformin in Association to Chemoradiotherapy for Locally Advanced Rectal Cancer | July 2015 | February 2016 |
| NCT00373113 | Terminated | Phase 3 | A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine | November 2006 | June 2011 |
| NCT00434941 | Terminated | Phase 2 | Capecitabine Plus Radiotherapy for Local Relapse Breast Cancer With Negative Her2 Tumours | September 2007 | January 2009 |
| NCT00354601 | Terminated | Phase 2 | Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer | January 2006 | July 2008 |
| NCT01955629 | Terminated | Phase 1/Phase 2 | Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient | December 2013 | March 2015 |
| NCT02767752 | Terminated | Phase 2 | Gemcitabine and Capecitabine With or Without T-ChOS as Adjuvant Therapy for Patients With Resected Pancreatic Cancer | November 2016 | July 2018 |
| NCT02780700 | Terminated | Phase 2 | Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2] | July 5, 2016 | September 9, 2016 |
| NCT00354224 | Terminated | Phase 2 | Capecitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Stomach Cancer | January 2005 | August 2008 |
| NCT00351195 | Terminated | Phase 2 | Etoposide, Oxaliplatin and Capecitabine in Advanced Hepatocellular Carcinoma (HCC) | February 2006 | April 2007 |
| NCT03387098 | Terminated | Phase 1/Phase 2 | QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | December 28, 2017 | January 15, 2019 |
| NCT04406857 | Terminated | Phase 1 | Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer | March 17, 2021 | January 18, 2023 |
| NCT00684216 | Terminated | Phase 2/Phase 3 | Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer | April 2008 | May 2013 |
| NCT00496366 | Terminated | Phase 2 | Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer | July 23, 2007 | March 20, 2017 |
| NCT01873833 | Terminated | Phase 2 | Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer | July 29, 2013 | March 2, 2021 |
| NCT00070122 | Terminated | Phase 3 | Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer | April 2004 | |
| NCT02485834 | Terminated | Phase 2 | FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer | August 2015 | August 2018 |
| NCT01450696 | Terminated | Phase 3 | A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer | December 2011 | August 2015 |
| NCT01355302 | Terminated | Phase 1/Phase 2 | E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer | November 2011 | July 2013 |
| NCT00889187 | Terminated | Phase 1/Phase 2 | Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer | December 2009 | December 30, 2011 |
| NCT00226941 | Terminated | Phase 1/Phase 2 | A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer | June 2004 | February 2009 |
| NCT00216138 | Terminated | Phase 2 | Docetaxel and Capecitabine for First Line Treatment of Metastatic Squamous Cell Carcinoma of the Head & Neck | March 2004 | September 2007 |
| NCT02910843 | Terminated | Phase 1 | Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal Cancer | February 22, 2017 | December 31, 2021 |
| NCT00959946 | Terminated | Phase 1/Phase 2 | Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer | September 2009 | March 2011 |
| NCT03878524 | Terminated | Phase 1 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | April 1, 2020 | December 10, 2020 |
| NCT00216086 | Terminated | Phase 2 | Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer | May 2005 | May 2008 |
| NCT00430027 | Terminated | N/A | Preoperative Capecitabine, Oxaliplatin, Cetuximab, and Radiation Therapy for Locally Advanced Esophageal Adenocarcinoma | November 2006 | August 2008 |
| NCT03376659 | Terminated | Phase 1/Phase 2 | Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma | August 8, 2018 | August 1, 2023 |
| NCT01280643 | Terminated | N/A | Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer | March 2010 | May 2014 |
| NCT01279681 | Terminated | Phase 3 | Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer | January 2011 | November 1, 2014 |
| NCT01267240 | Terminated | Phase 2 | Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer | December 2010 | October 2016 |
| NCT00347438 | Terminated | Phase 2 | Capecitabine as NeoAdjuvant Therapy in Locally Advanced Breast Cancer | September 2006 | March 2013 |
| NCT02010567 | Terminated | Phase 1/Phase 2 | Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer | December 2013 | June 25, 2019 |
| NCT00977379 | Terminated | Phase 2 | A Study of Whole Brain Radiation Therapy and Capecitabine in Breast Cancer Participants With Newly Diagnosed Brain Metastasis | August 2009 | February 2011 |
| NCT01233505 | Terminated | Phase 1 | Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors | October 2010 | |
| NCT01921751 | Terminated | Phase 2 | High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery | August 2013 | June 2016 |
| NCT01167738 | Terminated | Phase 2 | Combination Chemotherapy With or Without Metformin Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer | July 2010 | April 2015 |
| NCT03009058 | Terminated | Phase 1/Phase 2 | Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer | May 24, 2017 | August 30, 2017 |
| NCT00087334 | Terminated | Phase 1/Phase 2 | Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal Cancer | January 2004 | |
| NCT03026803 | Terminated | Phase 2 | A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer | November 2006 | October 2014 |
| NCT00216073 | Terminated | Phase 2 | Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer | March 2004 | October 2006 |
| NCT00201734 | Terminated | Phase 1/Phase 2 | Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary | June 2005 | June 2013 |
| NCT03050814 | Terminated | Phase 2 | Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004 | April 5, 2017 | August 25, 2021 |
| NCT00082095 | Terminated | Phase 3 | To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older | April 2004 | December 2005 |
| NCT01887288 | Terminated | Phase 2 | Capecitabine With Digoxin for Metastatic Breast Cancer | April 2013 | November 2015 |
| NCT00194792 | Terminated | Phase 2 | Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer | August 2005 | July 2011 |
| NCT01151761 | Terminated | Phase 2 | Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation | January 2011 | July 2012 |
| NCT01134601 | Terminated | Phase 1 | A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum | May 24, 2010 | October 22, 2012 |
| NCT01132664 | Terminated | Phase 1/Phase 2 | Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer | May 2010 | August 2014 |
| NCT00345059 | Terminated | Phase 3 | The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer | May 2005 | May 2008 |
| NCT03326674 | Terminated | Phase 3 | Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC | December 21, 2017 | June 28, 2021 |
| NCT01123473 | Terminated | Phase 2 | Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer | December 2010 | September 2014 |
| NCT03322215 | Terminated | Phase 2 | HR+/HER2- Advanced Breast Cancer and Endocrine Resistance | October 24, 2017 | October 31, 2023 |
| NCT03136406 | Terminated | Phase 1/Phase 2 | QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | August 11, 2017 | November 1, 2019 |
| NCT02524275 | Terminated | Phase 2 | Docetaxel and Capecitabine With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | March 30, 2015 | October 28, 2021 |
| NCT00335959 | Terminated | Phase 2 | S0425 Oxaliplatin, Capecitabine, and RT in Treating Patients W/Stomach Cancer That Can Be Removed By Surgery | May 2006 | |
| NCT01069796 | Terminated | Phase 2 | Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer | April 2010 | June 2014 |
| NCT03158610 | Terminated | Phase 2/Phase 3 | Biological-guided Metronomic Chemotherapy as Maintenance Strategy in Metastatic Colorectal Cancer | January 29, 2018 | April 28, 2021 |
| NCT00193102 | Terminated | Phase 2 | Thalidomide in Combination With Capecitabine in Patients With Metastatic Breast Cancer | April 2001 | June 2010 |
| NCT03300609 | Terminated | Phase 3 | 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab | February 27, 2018 | October 3, 2019 |
| NCT03300544 | Terminated | Phase 1 | Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer | May 14, 2019 | March 22, 2022 |
| NCT00081224 | Terminated | Phase 2 | Neoadjuvant Celecoxib and Capecitabine Combined With Pelvic Irradiation in Treating Patients With Stage II or Stage III Adenocarcinoma (Cancer) of the Rectum | December 2004 | November 2010 |
| NCT00070265 | Terminated | Phase 2 | Neoadjuvant and Adjuvant Capecitabine and Oxaliplatin in Treating Patients With Resectable Liver Metastases Secondary to Colorectal Cancer | August 2003 | |
| NCT00508274 | Terminated | Phase 3 | Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China | July 18, 2007 | July 1, 2020 |
| NCT00321100 | Terminated | Phase 2 | Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab | April 12, 2006 | December 18, 2013 |
| NCT02550743 | Terminated | Phase 1 | BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study | June 3, 2016 | November 16, 2018 |
| NCT00177255 | Terminated | Phase 2 | A Study of Docetaxel in Combination With Capecitabine in Stomach and Esophagus Cancers | April 2005 | December 2008 |
| NCT00538291 | Terminated | Phase 2 | Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment | August 2005 | |
| NCT03645876 | Terminated | Phase 2 | SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer | November 8, 2018 | April 18, 2019 |
| NCT04675983 | Terminated | Phase 3 | A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106) | March 10, 2021 | February 12, 2023 |
| NCT00176787 | Terminated | Phase 2 | Radiation Therapy With Capecitabine in Rectal Cancer | October 2000 | June 2007 |
| NCT02244489 | Terminated | Phase 1 | Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma | November 5, 2014 | April 5, 2017 |
| NCT02243007 | Terminated | Phase 2 | Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer | September 2014 | June 2016 |
| NCT00570908 | Terminated | Phase 2 | Brain Mets - Capecitabine Plus Sunitinib and WBRT | February 2009 | September 2013 |
| NCT00176735 | Terminated | N/A | Capecitabine and Radiation Therapy in Advanced Pancreatic Cancer | December 2001 | August 2005 |
| NCT00314353 | Terminated | Phase 2 | Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon | March 2006 | June 2010 |
| NCT00625183 | Terminated | Phase 2 | Capecitabine, Oxaliplatin, Selenomethionine, and Radiation Therapy in Treating Patients Undergoing Surgery For Newly Diagnosed Stage II or III Rectal Adenocarcinoma | March 2008 | December 2009 |
| NCT02216149 | Terminated | Phase 2 | Effects of S-1 and Capecitabine on Coronary Artery Blood Flow | January 2015 | August 2018 |
| NCT00305643 | Terminated | Phase 3 | Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer | February 2006 | October 2008 |
| NCT00541112 | Terminated | Phase 2 | Radiation Therapy, Chemotherapy, and Cetuximab Followed by Surgery, Chemotherapy, and Cetuximab in Treating Patients With Locally Advanced or Metastatic Rectal Cancer That Can Be Removed by Surgery | October 29, 2007 | January 29, 2010 |
| NCT00479856 | Terminated | Phase 2 | Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer | November 2007 | March 2010 |
| NCT00296062 | Terminated | Phase 1 | Dose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer | March 2006 | May 2011 |
| NCT02213744 | Terminated | Phase 2/Phase 3 | MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients | July 2014 | June 2017 |
| NCT00276744 | Terminated | Phase 2 | Individualized Drug Treatment for Treating Patients With Pancreatic Cancer | October 2005 | April 2010 |
| NCT02137343 | Terminated | Phase 3 | A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer | July 2014 | June 2015 |
| NCT01167049 | Unknown status | Phase 2 | Xeloda Plus Paclitaxel in Gastric Cancer With Liver Metastasis | August 2009 | December 2013 |
| NCT03678649 | Unknown status | Phase 2 | A Prospective Randomized Trial of Capecitabine Treatment in Patients With HNSCC | September 10, 2018 | December 30, 2023 |
| NCT03702985 | Unknown status | Phase 2 | Radiation-protection Effect of Amifostine in Locally Advanced Rectal Cancer | May 28, 2018 | March 1, 2020 |
| NCT00509561 | Unknown status | Phase 2/Phase 3 | Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer | February 2008 | |
| NCT02024009 | Unknown status | Phase 1/Phase 2 | Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer - 2 | March 2016 | August 2020 |
| NCT00496704 | Unknown status | Phase 1/Phase 2 | Gemcitabine, Capecitabine, and Oxaliplatin as Second-Line Therapy in Treating Patients With Advanced Colorectal Cancer Previously Treated With Irinotecan | January 2007 | |
| NCT03775928 | Unknown status | Phase 2 | Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer | December 18, 2018 | October 1, 2021 |
| NCT00482222 | Unknown status | Phase 3 | Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer | February 2007 | |
| NCT03779035 | Unknown status | Phase 3 | Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection | December 15, 2018 | December 31, 2023 |
| NCT03792269 | Unknown status | Phase 2 | Intraperitoneal and System Chemotherapy Versus XELOX as First-line Chemotherapy for mCRC | January 1, 2016 | December 2020 |
| NCT00453323 | Unknown status | Phase 2 | Paclitaxel and Capecitabine in Patients With Metastatic/Recurrence Esophageal Cancer | June 2006 | December 2010 |
| NCT03813641 | Unknown status | Phase 2 | RALOX or CAPOX + Bevacizumab in the First-line Treatment of Advanced CRC(ROCB Study) | January 28, 2019 | December 31, 2021 |
| NCT03813784 | Unknown status | Phase 3 | A Study to Evaluate SHR-1210 in Combination With Capecitabine + Oxaliplatin Sequenced by SHR-1210 + Apatinib as First-line Therapy in Treatment of Advanced Gastric Cancer | March 7, 2019 | March 2023 |
| NCT03817411 | Unknown status | Phase 2 | Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ Cancer | January 25, 2019 | January 25, 2021 |
| NCT03821454 | Unknown status | N/A | Capecitabine in the Treatment of Breast Cancer With Low-hormone Receptor Expression After Neoadjuvant Chemotherapy | February 1, 2019 | February 1, 2021 |
| NCT00450203 | Unknown status | Phase 2/Phase 3 | Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer | October 2007 | December 2017 |
| NCT00440167 | Unknown status | Phase 3 | Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine | June 2006 | December 2012 |
| NCT03873532 | Unknown status | Phase 2/Phase 3 | A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients | July 10, 2018 | March 2022 |
| NCT03889626 | Unknown status | Phase 3 | The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer | March 22, 2019 | March 22, 2024 |
| NCT00075556 | Unknown status | Phase 2 | Neoadjuvant Radiation Therapy and Capecitabine in Treating Patients With Stage III or Stage IV Colorectal Adenocarcinoma | January 2002 | |
| NCT00415285 | Unknown status | Phase 2 | Docetaxel Followed by Capecitabine Versus Concomitant Docetaxel/Capecitabine for Early Stage Breast Cancer | December 2006 | |
| NCT02022852 | Unknown status | Phase 2 | Neoadjuvant Sequential Therapy in Locally Advanced Mid/Low Rectal Cancer | July 2013 | January 2018 |
| NCT03923166 | Unknown status | Phase 2 | Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast Cancer | April 19, 2019 | December 31, 2021 |
| NCT03925233 | Unknown status | Breast Cancer Treatment Based on Organ-like Culture | January 2, 2019 | December 15, 2021 | |
| NCT00408408 | Unknown status | Phase 3 | Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery | November 2006 | March 2018 |
| NCT03959150 | Unknown status | Phase 2/Phase 3 | Metronomic Chemotherapy With Capecitabine for Pancreatic Cancer | January 5, 2020 | June 30, 2023 |
| NCT04008511 | Unknown status | Phase 1/Phase 2 | Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer | July 2019 | March 2024 |
| NCT00383695 | Unknown status | Phase 2 | Oxaliplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients Undergoing Surgery for High-Risk Rectal Cancer | September 2005 | |
| NCT04065282 | Unknown status | Phase 2 | The Purpose of This Study is to Evaluate the Efficacy and Safety of Sintilimab in Combination With Xelox as Neoadjuvant Therapy for Patients With Resectable Locally Advanced Gastric or Gastroesophageal Adenocarcinoma. | August 6, 2019 | March 1, 2022 |
| NCT02403544 | Unknown status | Phase 1 | Phase I Study of Image-Guided Radiation Concurrent With Double-Agent Chemotherapy for Hepatocellular Carcinoma | September 2013 | December 2016 |
| NCT04095390 | Unknown status | Phase 2 | A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer | September 30, 2019 | August 30, 2022 |
| NCT04097444 | Unknown status | Phase 2 | CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC | October 11, 2019 | August 31, 2022 |
| NCT00324610 | Unknown status | Phase 1/Phase 2 | Tolerance and Pharmacokinetics With Capecitabine 5 Out of 7 Days Regimen | March 2006 | |
| NCT04185649 | Unknown status | Phase 3 | The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer | July 1, 2018 | December 31, 2021 |
| NCT02007148 | Unknown status | Phase 2 | MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer | November 2013 | May 2022 |
| NCT04202978 | Unknown status | Phase 1/Phase 2 | Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal Cancer | March 1, 2020 | November 1, 2021 |
| NCT02422199 | Unknown status | Phase 1/Phase 2 | A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab | May 2015 | December 2018 |
| NCT05291052 | Unknown status | Phase 2 | Tisleizumab Combined With Lenvatinib and XELOX Regimen (Oxaliplatin Combined With Capecitabine) in the First-line Treatment of Advanced and Unresectable Biliary Tract Tumors | February 14, 2022 | March 30, 2024 |
| NCT00303745 | Unknown status | Phase 2 | Irinotecan With or Without Capecitabine as Second-Line Therapy in Treating Older Patients With Progressive, Metastatic Colorectal Cancer That Cannot Be Removed By Surgery | June 2006 | |
| NCT02002195 | Unknown status | Modified Folinic Acid-Fluorouracil-Oxaliplatin Regimen + Capecitabine for Elderly With Metastatic Gastric Cancer | November 2013 | May 2022 | |
| NCT04281576 | Unknown status | N/A | Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Chemotherapy as First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma | December 19, 2019 | September 2021 |
| NCT04295317 | Unknown status | Phase 2 | PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients With Intrahepatic Cholangiocarcinoma After Surgery | August 1, 2020 | February 28, 2024 |
| NCT04296162 | Unknown status | Phase 2 | Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID) | March 1, 2019 | May 30, 2021 |
| NCT04302441 | Unknown status | Phase 2 | A Study to Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab for HER2 Positive Patients Following Neoadjuvant Chemotherapy | November 10, 2016 | June 30, 2021 |
| NCT04307147 | Unknown status | Phase 3 | NX in Luminal B Breast Cancer Patients After Neoadjuvant Chemotherapy | July 3, 2018 | September 1, 2021 |
| NCT01963702 | Unknown status | Phase 2 | A Phase II Trial of Exploring the Predictive Factors of TX and XELOX Regimen in the First Line Treatment of MGC | August 2012 | December 2014 |
| NCT05321329 | Unknown status | Phase 2 | Adjuvant CAPECITABINE in High Risk PSEUDOMYXOMA PERITONEI Patients | December 3, 2018 | December 2023 |
| NCT04340401 | Unknown status | Phase 2 | Total Neoadjuvant Treatment Plus SHR1210 for High-risk Rectal Cancer and Biomarker Screening Base on Neoantigen | May 25, 2020 | April 2022 |
| NCT00026442 | Unknown status | Phase 2 | Capecitabine in Treating Women With Advanced or Metastatic Breast Cancer | November 2001 | |
| NCT04390958 | Unknown status | Phase 2 | Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | May 15, 2020 | December 2022 |
| NCT04394598 | Unknown status | Phase 2 | A Study of Chinese Herbal Compound Dendrobium Huoshanense Granules in NCRT for Patients With Locally Advanced Rectal Cancer | March 1, 2020 | December 1, 2022 |
| NCT04404491 | Unknown status | Phase 3 | Clinical Control Study of Immunotherapy and Concurrent Chemoradiotherapy in Patients With Esophageal Cancer Recurrence | June 1, 2020 | June 30, 2023 |
| NCT04405206 | Unknown status | Total Neoadjuvant Therapy Followed by 'Watch and Wait' Approach or Organ Preservation for Low-risk Rectal Cancer | May 25, 2020 | December 30, 2023 | |
| NCT04411524 | Unknown status | Phase 2 | The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSI-H Locally Advanced Rectal Cancer | July 1, 2020 | December 31, 2022 |
| NCT04411537 | Unknown status | Phase 2 | The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSS Locally Advanced Rectal Cancer | July 1, 2020 | December 31, 2022 |
| NCT01939054 | Unknown status | Phase 2 | Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer Patients | September 2013 | September 2016 |
| NCT00049244 | Unknown status | Phase 1 | BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer | September 2002 | |
| NCT01924078 | Unknown status | Phase 2 | Capecitabine Metronomic Chemotherapy Plus Aromatase Inhibitor for Postmenopausal Hormone Receptor Positive Breast Cancer | October 2010 | June 2015 |
| NCT05429684 | Unknown status | Phase 3 | Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer | January 1, 2021 | February 28, 2024 |
| NCT02514681 | Unknown status | Phase 3 | A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer | August 1, 2015 | December 2021 |
| NCT04571437 | Unknown status | Phase 2 | Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study) | March 1, 2020 | April 30, 2022 |
| NCT02526953 | Unknown status | Phase 3 | Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients | January 2016 | October 2022 |
| NCT04608786 | Unknown status | Phase 1 | A Clinical Study of PD-L1 Antibody ZKAB001 Combined With Capecitabine in Resected Biliary Tract Cancer | February 1, 2021 | December 1, 2023 |
| NCT02548195 | Unknown status | Phase 3 | Oxaliplatin+Gemcitabine vs Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma | July 2015 | December 2018 |
| NCT00182715 | Unknown status | Phase 3 | Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer | March 2005 | |
| NCT01899118 | Unknown status | Phase 2 | Nimotuzumab in Combination With Chemoradiation in Patients With Locally Advanced Rectal Cancer | April 2013 | |
| NCT01880658 | Unknown status | Phase 2 | Phase II Study of Maintenance Capecitabine to Treat Resectable Colorectal Cancer | June 2013 | May 2019 |
| NCT02250209 | Unknown status | Phase 2 | T- XELOX in HER2-positive Stage III Gastric Cancer After D2 Gastrectomy | July 2014 | December 2017 |
| NCT00156975 | Unknown status | Phase 3 | Oxaliplatin and Capecitabine Versus Follow-up After Resection of Colorectal Liver Metastases | November 2004 | |
| NCT04745975 | Unknown status | Phase 2 | Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer | February 1, 2021 | January 2023 |
| NCT00058474 | Unknown status | Phase 3 | Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer | July 2004 | May 2016 |
| NCT04780347 | Unknown status | Phase 2 | Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast Cancer | December 15, 2020 | February 25, 2023 |
| NCT02268006 | Unknown status | Phase 2 | IMRT-SIB and Capecitabine in Preoperative Rectal Cancer Treatment | January 2014 | December 2020 |
| NCT02177552 | Unknown status | Phase 2 | Study Assessing the Effects of Chemotherapy in Advanced Esophagogastric Adenocarcinoma | June 2014 | November 2019 |
| NCT04802980 | Unknown status | Phase 1 | A Study of HB002.1T Plus Chemotherapy in Subjects With Solid Tumor | April 28, 2020 | September 2023 |
| NCT02289547 | Unknown status | Phase 3 | Phase 3 Study of Xelox Followed by Maintenance Capecitabine in the Advanced Gastric Cancer | May 2015 | January 2019 |
| NCT00122291 | Unknown status | Phase 2 | A Study of Preoperative Radiation Therapy and Capecitabine in Locally Advanced Rectal Cancer | January 2002 | |
| NCT04963088 | Unknown status | Phase 1/Phase 2 | TISLELIZUMAB Combined With Anlotinib and Chemotherapy(XELOX) in the Treatment of Advanced Gastric Carcinoma | March 6, 2021 | March 20, 2024 |
| NCT02316535 | Unknown status | Phase 3 | Low-dose Capecitabine Adjuvant Chemotherapy for Elderly Patients With Stage II/III Colorectal Cancer | November 2014 | May 2018 |
| NCT05018182 | Unknown status | Phase 2 | FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer | August 2, 2021 | August 2, 2022 |
| NCT02115152 | Unknown status | Phase 2 | Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer | June 2014 | |
| NCT02350686 | Unknown status | Phase 2 | XELOX in Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy | May 14, 2015 | December 2020 |
| NCT05089643 | Unknown status | Phase 2 | Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer | April 11, 2019 | December 31, 2022 |
| NCT01843829 | Unknown status | Phase 2 | A Feasibility Study of Chemo-radiotherapy to Treat Operable Oesophageal Cancer | October 2013 | May 2016 |
| NCT01798251 | Unknown status | Phase 2 | XELOX With Capecitabine Maintenance or XELOX in Elderly Metastatic Adenocarcinoma of Stomach | December 2012 | December 2015 |
| NCT02592746 | Unknown status | Phase 2 | A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC | June 2016 | June 2021 |
| NCT02595320 | Unknown status | Phase 2 | Capecitabine in Metastatic Breast and GI Cancers | October 5, 2015 | December 2023 |
| NCT02597868 | Unknown status | N/A | A Multicenter, Randomized Clinical Trail Evaluate Effectiveness and Security of Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen After the 1st-line Chemotherapy With Capecitabine Combine Regimen in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer(Overstep) | January 2013 | July 2017 |
| NCT02605265 | Unknown status | Phase 3 | Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1 | October 2015 | December 2020 |
| NCT02623153 | Unknown status | Phase 2 | Comparison Between XELOX and S1, Oxaliplatin and Docetaxel as Neoadjuvant Chemotherapy for Gastric Cancer | January 2016 | December 2019 |
| NCT01716949 | Unknown status | Phase 1/Phase 2 | Neoadjuvant Chemoradiation With 5-FU(or Capecitabine) and Oxaliplatin Combined With Hyperthermia in Rectal Cancer | September 2012 | June 2023 |
| NCT02633176 | Unknown status | Phase 3 | Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma | January 2015 | |
| NCT02656589 | Unknown status | microRNA of Human Epidermal Growth Factor Receptor 2 （HER2）Positive Patient Treated With Herceptin | June 2015 | June 2018 | |
| NCT01609127 | Unknown status | Phase 2 | Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer | May 2012 | July 2014 |
| NCT02736448 | Unknown status | Phase 2 | 177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors | May 2016 | June 2021 |
| NCT02741856 | Unknown status | Phase 2/Phase 3 | Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose Escalation | November 4, 2016 | April 2023 |
| NCT01591733 | Unknown status | Phase 2 | FOLFIRINOX + RT for Pancreatic Cancer | May 2012 | January 2022 |
| NCT01573468 | Unknown status | Phase 2 | Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer | April 2012 | August 2014 |
| NCT01552967 | Unknown status | Phase 2 | Efficacy and Safety Study of a Modified XELOX Regimen in First-Line Treatment of Metastatic Colorectal Adenocarcinoma | March 2012 | February 2014 |
| NCT02798510 | Unknown status | Phase 3 | Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma | April 2016 | |
| NCT02838238 | Unknown status | Phase 2 | X Versus Placebo as Postoperative Adjuvant Treatment for Elder Breast Cancer | January 2014 | |
| NCT01549795 | Unknown status | N/A | Liver Transplantation for Hilar Cholangiocarcinoma in Association With Neoadjuvant Radio- and Chemo-therapy | January 2012 | |
| NCT02854072 | Unknown status | Phase 3 | A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer Patients | November 2015 | May 2018 |
| NCT01494155 | Unknown status | Phase 2 | Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer | December 2011 | January 2023 |
| NCT01474187 | Unknown status | Phase 1 | Genotype-driven Phase I Study of Irinotecan Administered in Neoadjuvant Chemoradiotherapy in Patients With Stage II/III Rectal Cancer | November 2011 | December 2012 |
| NCT01468389 | Unknown status | Phase 3 | Taxanes or Platinum in Combination With Capecitabine Followed by Capecitabine Alone as First Line Treatment for Patients With Advanced Adenocarcinoma of Stomach or Esophagogastric Junction | November 2011 | June 2013 |
| NCT02893540 | Unknown status | Phase 2/Phase 3 | Metronomic Versus Conventional Chemotherapy in as Maintenance Treatment in mCRC | September 2016 | August 2019 |
| NCT02901301 | Unknown status | Phase 1/Phase 2 | Pembrolizumab, Trastuzumab, HER2 Positive Gastric Cancer | February 6, 2017 | October 2021 |
| NCT02919878 | Unknown status | Phase 2 | Neo-adjuvant Chemoradiotherapy Using Infusional Gemcitabine Followed by Surgery for Locally Advanced Rectal Cancer | December 2014 | December 2019 |
| NCT01333332 | Unknown status | Phase 2 | Radiotherapy With Chemotherapy as Neoadjuvant Therapy of Resectable and Borderline Resectable Pancreas Cancer | August 2010 | |
| NCT01308086 | Unknown status | Phase 3 | Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer | October 2010 | December 2017 |
| NCT01249638 | Unknown status | Phase 3 | Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC | December 2010 | December 2016 |
| NCT02958111 | Unknown status | Phase 3 | Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma | January 2017 | December 2023 |
| NCT01231802 | Unknown status | Phase 2 | Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer | April 2011 | January 2013 |
| NCT03042000 | Unknown status | N/A | Multicenter, Prospective, RCT：Investigation of Combined Modality Therapy for Locally Advanced Mid/Low Rectal Cancer. | February 2017 | December 2021 |
| NCT03044730 | Unknown status | Phase 2 | Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery | May 25, 2017 | May 2021 |
| NCT01167725 | Unknown status | Phase 3 | Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer | August 2010 | |
| NCT00514293 | Unknown status | Phase 2 | Bexarotene, Tretinoin, and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | January 2007 | |
| NCT03114085 | Unknown status | Phase 2 | Apatinib Combined With Capecitabine Compared With Apatinib Treat Advanced Hepatocellular Carcinoma | May 20, 2017 | May 20, 2019 |
| NCT01097265 | Unknown status | Phase 2/Phase 3 | Study of Micrometastases in Patients With Stage I or Stage II Localized Colon Cancer That Can Be Removed by Surgery | July 2010 | |
| NCT01079702 | Unknown status | Phase 1/Phase 2 | Everolimus and Capecitabine in Patients With Advanced Malignancy | April 2008 | January 2011 |
| NCT02068131 | Unknown status | Phase 2 | Recombinant Anti-tumor and Anti-virus Protein for Injection Plus Xeloda in Treatment of Metastatic Colorectal Cancer | February 2014 | December 2016 |
| NCT03204734 | Unknown status | Phase 2 | Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer | January 1, 2016 | December 30, 2021 |
| NCT02043821 | Unknown status | N/A | Maintenance Chemotherapy for Metastatic Colorectal Carcinoma and Biological Marker | ||
| NCT01064999 | Unknown status | Phase 2/Phase 3 | A Trial of High Intensity Versus Low Intensity Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer | March 2010 | December 2014 |
| NCT02028494 | Unknown status | N/A | Evaluation of Response to Two Schedules of Capecitabine in Patients With Metastatic Breast Cancer | August 2013 | March 2019 |
| NCT01015339 | Unknown status | Phase 3 | Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction | November 2009 | August 2015 |
| NCT00985556 | Unknown status | Phase 2 | Oxaliplatin and S-1 or Oxaliplatin and Capecitabine in Treating Patients With Recurrent, Metastatic, or Unresectable Gastric Cancer | January 2009 | |
| NCT03349866 | Unknown status | Phase 2 | A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ，III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction | November 30, 2017 | November 30, 2020 |
| NCT03368131 | Unknown status | Phase 2 | Concurrent Neoadjuvant Chemoradiotherapy Plus Trastuzumab in the Treatment of Siewert II ，III of Human Epidermal Growth Factor Receptor-2(HER-2) Positive Gastroesophageal Junction Adenocarcinoma： A Randomized, Controlled Clinical Study | December 1, 2017 | December 31, 2020 |
| NCT00967655 | Unknown status | Phase 2 | Capecitabine, Panitumumab, and Radiation Therapy With or Without Irinotecan Hydrochloride in Treating Patients Undergoing Surgery for Localized Rectal Cancer | July 2009 | |
| NCT03381352 | Unknown status | Phase 2 | Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer | December 2, 2015 | December 31, 2020 |
| NCT03387592 | Unknown status | Phase 2 | CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas | March 6, 2017 | January 2022 |
| NCT00821912 | Unknown status | Phase 1/Phase 2 | TaxXel: Taxotere and Xeloda in Esophageal Cancer | March 2006 | September 2013 |
| NCT02371304 | Unknown status | Phase 3 | Rectal Preserving Treatment for Early Rectal Cancer. A Multi-centred Randomised Trial of Radical Surgery Versus Adjuvant Chemoradiotherapy After Local Excision for Early Rectal Cancers | October 2015 | January 2023 |
| NCT03423849 | Unknown status | Phase 2/Phase 3 | The Maintenance Regimen and Revised Regimen for Advanced Breast Cancer Survivors After First-line Salvage Therapy | February 8, 2018 | February 8, 2020 |
| NCT03435666 | Unknown status | Phase 1 | A Bioequivalence Study of Capecitabine Tablets 500 mg in Adult Cancer Patients Under Fed Condition | May 2018 | November 2018 |
| NCT03448835 | Unknown status | Phase 2 | Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA) | March 7, 2018 | January 1, 2022 |
| NCT00797485 | Unknown status | Phase 3 | Bevacizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Metastatic Colorectal Cancer That Cannot Be Removed By Surgery | July 2008 | |
| NCT03465202 | Unknown status | Phase 4 | Association of Capecitabine Pharmacokinetics and Toxicity With Aging | May 2016 | November 2019 |
| NCT00726687 | Unknown status | Phase 1/Phase 2 | Phase 1b Study of Indibulin in Combination With Capecitabine in Advanced Solid Tumors | June 2008 | June 2013 |
| NCT00674167 | Unknown status | Phase 2 | The Effect of Preoperative Docetaxel, Cisplatin and Capecitabine on Serum RUNX3 Hypermethylation Status in Patients With Gastric and Lower Oesophagus Adenocarcinoma | May 2007 | December 2017 |
| NCT00647530 | Unknown status | Phase 2/Phase 3 | Fluorouracil and Oxaliplatin With or Without Panitumumab In Treating Patients With High-Risk Colon Cancer That Can Be Removed by Surgery | May 15, 2008 | December 31, 2019 |
| NCT02027363 | Unknown status | Phase 2 | Maintenance Treatment With Capecitabine in Colorectal Cancer Patients | January 2010 | June 2014 |
| NCT00577057 | Unknown status | N/A | Benefit of Changing Chemoradiotherapy Sequence and Modifying Radiotherapy Schedule for Advanced Nasopharyngeal Cancer | September 2006 | August 2013 |
| NCT00561522 | Unknown status | Phase 2/Phase 3 | Capecitabine to Prevent Recurrence of Hepatocellular Carcinoma After Curative Resection | November 2007 | July 2012 |
| NCT03588533 | Unknown status | Phase 2 | Herzuma-capecitabine/Cisplatin for Gastric Cancer | June 10, 2018 | August 31, 2021 |
| NCT00544011 | Unknown status | Phase 2 | Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer | April 2007 | |
| NCT03609489 | Unknown status | Phase 2 | A Study to Investigate Apatinib Combined Capecitabine on Adjuvant Therapy of Biliary Carcinoma | September 10, 2018 | December 25, 2021 |
| NCT03638648 | Unknown status | Phase 2 | Recurrence Score-guiding Chemotherapy in Non-pCR HR Positive HER2 Negative Breast Cancer After Neoadjuvant Therapy | November 1, 2019 | December 30, 2022 |
| NCT02586610 | Withdrawn | Phase 2 | Trial of Chemoradiation and Pembrolizumab in Patients With Rectal Cancer | October 2016 | December 2020 |
| NCT05238831 | Withdrawn | Early Phase 1 | SMMART Adaptive Clinical Treatment (ACT) Trial | January 30, 2023 | May 31, 2026 |
| NCT00095641 | Withdrawn | Phase 2 | S0225 Capecitabine in Treating Patients Who Have Undergone Surgery for Locally Recurrent or Persistent Head and Neck Cancer | ||
| NCT00524069 | Withdrawn | N/A | Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery | January 2007 | |
| NCT00503932 | Withdrawn | Phase 1/Phase 2 | Proton Therapy With Capecitabine for Rectal Cancer | July 2007 | April 2008 |
| NCT03563144 | Withdrawn | Phase 2 | QUILT-3.088: NANT Pancreatic Cancer Vaccine | August 2018 | December 30, 2019 |
| NCT02085005 | Withdrawn | Phase 2 | Capecitabine Plus Aflibercept as Maintenance Therapy Following Capecitabine Plus Oxaliplatin Plus Aflibercept in Patients With Metastatic Colorectal Cancer | March 2014 | August 2016 |
| NCT00408772 | Withdrawn | Phase 2 | Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer | June 2007 | April 2008 |
| NCT03563170 | Withdrawn | Phase 1/Phase 2 | QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine | May 25, 2018 | August 23, 2019 |
| NCT03708536 | Withdrawn | Phase 3 | Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma | November 2018 | November 2022 |
| NCT03169764 | Withdrawn | Phase 1/Phase 2 | QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy | December 2017 | March 2019 |
| NCT03169777 | Withdrawn | Phase 1/Phase 2 | QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC | August 2018 | March 2019 |
| NCT03169790 | Withdrawn | Phase 1/Phase 2 | QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL | December 2017 | March 2019 |
| NCT03175666 | Withdrawn | Phase 1/Phase 2 | QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy | December 2017 | March 2019 |
| NCT03197571 | Withdrawn | Phase 1/Phase 2 | QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy | December 2017 | March 2019 |
| NCT03197584 | Withdrawn | Phase 1/Phase 2 | QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy | December 2017 | April 2019 |
| NCT03579758 | Withdrawn | Phase 3 | Chemotherapy Before & After Surgery in Patients With Resectable Gallbladder Cancer | April 3, 2019 | June 1, 2020 |
| NCT00118105 | Withdrawn | Phase 2 | S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer | November 2006 | April 2007 |
| NCT00118300 | Withdrawn | Phase 1 | Capecitabine and Radiation Therapy in Treating Patients With Locally Advanced Cervical Cancer or Other Pelvic Cancer | April 2005 | |
| NCT01017822 | Withdrawn | Phase 1/Phase 2 | Conatumumab, Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer | ||
| NCT00119314 | Withdrawn | Phase 2 | Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin | July 2004 | July 2005 |
| NCT03169738 | Withdrawn | Phase 1/Phase 2 | QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors | February 2018 | March 2019 |
| NCT05227131 | Withdrawn | Phase 2 | Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer | May 15, 2022 | October 2024 |
| NCT03167177 | Withdrawn | Phase 1/Phase 2 | QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy | December 2017 | March 2019 |
| NCT03167164 | Withdrawn | Phase 1/Phase 2 | QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy | December 2017 | March 2019 |
| NCT03129074 | Withdrawn | Phase 2 | Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer | May 2018 | September 2020 |
| NCT03117855 | Withdrawn | Phase 1 | Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery | December 2016 | |
| NCT04859582 | Withdrawn | Phase 3 | Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension | November 8, 2018 | November 29, 2024 |
| NCT00070434 | Withdrawn | Phase 2 | S0304 Induct Chemo Then Chemo-RT in Pts w/Locally Advanced Adenocarcinoma of the Rectum | August 2004 | |
| NCT01245582 | Withdrawn | Phase 3 | Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma Patients | July 2011 | August 2015 |
| NCT04037241 | Withdrawn | Phase 2/Phase 3 | Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases | November 1, 2021 | January 1, 2022 |
| NCT00450515 | Withdrawn | Phase 2 | Vinflunine and Capecitabine in Treating Patients With Previously Treated Metastatic Breast Cancer | March 2007 | January 2009 |
| NCT01302613 | Withdrawn | Phase 1/Phase 2 | Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma | March 2011 | November 2012 |
| NCT00960544 | Withdrawn | Phase 2 | Correlation of Genomic Variation in Enzymes Responsible for Metabolism of Capecitabine With Drug Metabolism | January 2019 | January 2021 |
| NCT00397761 | Withdrawn | Phase 2/Phase 3 | Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer | July 2006 | |
| NCT02915172 | Withdrawn | Phase 1 | Lenvatinib and Capecitabine in Patients With Advanced Malignancies | December 2016 | |
| NCT01349088 | Withdrawn | Phase 1/Phase 2 | Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer | December 2013 | September 2018 |
| NCT02831179 | Withdrawn | Phase 1 | Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor | December 2017 | February 2020 |